CN109609647A - Detection Panel, detection kit and its application for the targeting of general cancer kind, chemotherapy and immune medication based on the sequencing of two generations - Google Patents
Detection Panel, detection kit and its application for the targeting of general cancer kind, chemotherapy and immune medication based on the sequencing of two generations Download PDFInfo
- Publication number
- CN109609647A CN109609647A CN201910074640.XA CN201910074640A CN109609647A CN 109609647 A CN109609647 A CN 109609647A CN 201910074640 A CN201910074640 A CN 201910074640A CN 109609647 A CN109609647 A CN 109609647A
- Authority
- CN
- China
- Prior art keywords
- fus
- detection
- relevant
- general cancer
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of detection panel, detection kit and its applications for the targeting of general cancer kind, chemotherapy and immune medication based on the sequencing of two generations.Wherein, detection panel includes general cancer kind parting, treatment, the relevant gene mutation of prognosis, the relevant exon region of Tumor mutations carry calculation and microsatellite instability site.It applies the technical scheme of the present invention, detecting panel includes general cancer kind parting, treatment, the relevant gene mutation of prognosis, the relevant exon region of Tumor mutations carry calculation and microsatellite instability site, the gene information that it includes is comprehensive, it can directly make a variation to kinds of tumors and carry out joint-detection, applied to targeting medicine, the available accurately result of adjoint diagnosis of chemotherapeutic or immune substance.
Description
Technical field
The present invention relates to field of biomedicine technology, are used for general cancer kind based on the sequencing of two generations in particular to a kind of
Detection panel, detection kit and its application of targeting, chemotherapy and immune medication.
Background technique
Currently, there are many relevant detection technique of cancer, for example, high-flux sequence, target area capture sequencing, liquid biopsy,
Tumor mutations load and MSI detection etc..
Wherein, high-flux sequence (High-Throughput Sequencing) also known as next-generation sequencing (Next
Generation Sequencing, NGS), it is for (Sanger Sequencing) is sequenced in traditional mulberry lattice.
On the basis of the sequencing approaches such as Sanger, by technological innovation, the genomic DNA two sides of fragmentation is connected and are connect
Head then generates the PCR clone's array fixed in millions of a spaces with different methods.Each clone is by single library fragments
Multiple copy compositions.Then primer hybridization and enzyme extension are carried out.All in the same plane due to all clones
(flowcell), with four kinds of different dNTP of the fluorescent marker of different colours, when archaeal dna polymerase synthesizes complementary strand, every addition
A kind of dNTP will release different fluorescence, and DNA sequence dna extends and image checking constantly repeats, and finally analyze by computer
It is obtained with complete DNA sequence dna information.Once sequencing is carried out to millions of nucleic acid molecules to hundreds of thousands to be also known as deeply
Degree sequencing (Deep sequencing).
NGS detection method flux is high, and same sample only needs to carry out a library construction and capture, so that it may to a large amount of
Gene is detected, and meets the needs of clinical detection, and the detection of multiple genes can be carried out by not needing a large amount of sample size, both may be used
To be detected to known mutations site, unknown mutation site can also be detected, furthermore NGS detection method can also be to each
Kind of mutation type is detected, to Different categories of samples clinically, such as whole blood, tissue, FFPE sample, cfDNA other sample classes
Type is able to carry out detection.
The application being derived in conjunction with microarray technology is sequenced in target area capture sequencing, the second generation, and target sequence is caught
Obtain sequencing technologies (Targeted Resequencing).This technology synthesizes a large amount of oligonucleotides first with microarray technology
Probe, these oligonucleotide probes complementary with the specific region on genome can combine, to be enriched to particular section, then
These sections are sequenced with second generation sequencing technologies.It is to utilize target gene group based on DNA hybridization principle that principle, which is sequenced, in it
The probe and genomic DNA of region customization carry out chip hybridization or solution hybridization, and target gene regions DNA is enriched with, then passes through
NGS technology is sequenced.Selected target area, which is sequenced, can be continuous DNA sequence dna, be also possible to be distributed in same
Segment in chromosome different zones or different chromosomes.
Liquid biopsy is exactly to pass through acquisition blood or urine etc. to make diagnosis to diseases such as cancers.It is living with traditional operation
Inspection is compared with aspiration biopsy, and the advantage of liquid biopsy is: 1) easy to operate, traditional biopsy depends on the discovery of iconography, fixed
Operation or puncture procedure are carried out after the accurate location and size of position tumour, operability is difficult, and liquid biopsy does not need image then
It learns and supports；2) non-intrusion type, traditional mode is due to its intrusive mood operation, often with complication, tumor recurrence risk, liquid
Biopsy is then only to extract a certain amount of blood, and risk is small；3) sampling is convenient.Tradition punctures and operation samples this and injures to patient
It is larger, and liquid biopsy generally only needs 5~10ml blood, supports to be repeated as many times sampling；4) Tumor Heterogeneity is successfully managed.It passes
System sampling is likely to occur the problem of taking less than tumor tissues by the reason of sampling point, and may be swollen comprising different mutation in blood
The information of oncocyte.5) at low cost.It is cheap compared with traditional detection method.
Tumor mutations load (TMB) is that displacement occurs in the every megabasse of exons coding district for assess gene and is inserted into/lacks
The sum for losing mutation, the completely new biomarker with good prospect, TMB can genetic coding region in quantitative predication tumor sample
Mutation sum.Tumour cell with higher level TMB is easier to be identified by immune system, the reason is that the mutation of body cell
It is transcribed/to be expressed as RNA/ protein level, new antigen, protein fragments or polypeptide segment etc. are generated, these new albumen are by itself
Immune system is identified as non-self antigen, activates T cell, causes to be immunoreacted.Therefore, when the gene accumulated in every megabasse becomes
When heteromerism mesh increases, so that it may many new antigens are generated, it is easier to be identified by immunocyte.So as to inhibit to checkpoint
Agent has stronger immune response, that is to say, that TMB is higher, and patient perhaps benefits in bear immunization therapy more.Currently, very much
All confirmed in research TMB and tumor neogenetic antigen to the curative effect of immunologic test point inhibitor be it is relevant, utilize advanced two generation
Sequencing technologies, exon sequencing approach detect Tumor mutations load, provide solution for clinic personalized treatment.
Microsatellite (Microsatellite) is the short tandem repeat being dispersed throughout in human genome, there is monokaryon glycosides
The repetition of acid, dinucleotide or high-order nucleotide, number of repetition 10~50 times.It is micro- in tumour cell compared with normal cell
Satellite due to recurring unit insertion or missing and lead to the change of microsatellite length, be just called microsatellite instability (MSI,
microsatellite instability).A large number of studies show that MSI is that defect occurs by mispairing reparation (MMR) gene to cause
, it is closely related with the generation of tumour.MMR system is made of a series of enzyme of specific DNA plerosis base mispairings, they can
The mispairing occurred in DNA replication dna and damage process or the base that do not match are found and corrected, guarantees the accuracy of duplication.When tumour is thin
There are when MMR gene lacks functionality (Mis-Match Repair deficiency, abbreviation dMMR) in born of the same parents, signal tumor cell
The repair ability to DNA replication dna mistake is lost, will build up on mass mutation in tumour cell, adjoint microsatellite instability will occur
Property (MSI) feature, cause cell proliferation and differentiation abnormal and the generation of tumour.MSI is the label for evaluating MMR system function.According to
MSI unstability and degree, can be divided into the highly unstable type of microsatellite (MSI-H), microsatellite minuent instability mode (MSI-L) and
Microsatellite stable type (MSS).MSI detection can be used for: 1) II phase colorectal cancer patients medication guide and prognosis prediction；2)Lynch
The screening of (Jessica Lynch) syndrome；2) the benefit prediction of PD-1 immunization therapy.Detection method: while extracting normal group of same patient
It knits with tumor tissues sample DNA, detection site is expanded using the method for multiple fluorescence PCR, then pass through Capillary Electrophoresis
Amplified production is detected, and two kinds of tissue-derived testing results are compared and analyzed using professional software, it can accurately
Parting is carried out to patient's MSI state.
But every kind of detection method deposits different advantage and disadvantage, product currently on the market can not be treated comprehensively
Test sample is originally detected.
Summary of the invention
The present invention is intended to provide a kind of detection for the targeting of general cancer kind, chemotherapy and immune medication based on the sequencing of two generations
Panel, detection kit and its application, with solve in the prior art cannot the technology that is detected of comprehensive sample to be tested ask
Topic.
To achieve the goals above, according to an aspect of the invention, there is provided it is a kind of based on the sequencing of two generations for general
The detection panel of the targeting of cancer kind, chemotherapy and immune medication.Detection panel includes for carrying out the general cancer kind of joint-detection point
Type, treatment, the relevant gene mutation of prognosis, the relevant exon region of Tumor mutations carry calculation and microsatellite instability position
Point.
Further, general cancer kind parting, treatment, the relevant gene mutation of prognosis, Tumor mutations carry calculation are relevant outer
Aobvious subregion include ABCA13, ABCA8, ABL1, ACADSB, ACOT13, ADAMTS6, ADRB1, ADSS, AGPAT9, AK7,
AKT1、AKT2、AKT3、ALG9、ALK、ALK_fus、ALOX12B、ALS2CR11、AMER1、ANKRA2、ANKRD46、ANO1、
APC、APOPT1、AR、ARAF、ARHGAP4、ARHGAP6、ARID1A、ARID1B、ARID2、ARID4A、ARL6IP6、ARMC5、
ARPC2、ASH1L、ASXL1、ATM、ATP9B、ATR、ATRX、AURKA、AURKB、AXIN1、AXL、B2M、BAP1、BARD1、
BAT-25、BAT-26、BCL2、BCL2L1、BCOR、BCYRN1、BLM、BRAF、BRCA1、BRCA2、BRD4、BRIP1、BRS3、
BTF3、BTG1、BTK、C20orf96、C22orf23、C5orf42、C9orf72、CAB39、CALD1、CALM2、CALR、
CARD11、CASP8、CAST,ERAP1、CBFB、CBL、CBR4、CCND1、CCND2、CCND3、CCNE1、CCR4、CD274、
CD40、CD74_fus、CD79A、CD79B、CDC25B、CDC73、CDH1、CDK12、CDK4、CDK6、CDK7、CDK8、CDKL3、
CDKN1A、CDKN1B、CDKN2A、CDKN2B、CDKN2C、CDO1、CEBPA、CEP120、CHD1、CHEK1、CHEK2、CIC、
CNKSR3、CNOT8、COSM1316144、COSM1316145、COSM1332498、COSM3676668、COSM3747491、
COSM5045664、COX18、CREBBP、CRKL、CRLF2、CSF1R、CSF3R、CTAGE5、CTCF、CTNNB1、CUL3、
CXCR4、CYFIP1、CYLD、DAXX、DBT、DDR2、DEPDC5、DIAPH1、DICER1、DIS3、DNMT3A、DOCK11、
DOT1L、DROSHA、DSCAM、DXS6804、DXS7132、DXS7423、DYS391、DYS438、DYS458、EGFR、EGFR_
fus、EIF4G3、EML4_fus、EP300、EPHA3、EPHA5、EPHA7、EPHB1、ERBB2、ERBB3、ERBB4、ERCC4、
ERG、ERI1、ERRFI1、ESR1、ETV1、ETV6、ETV6_fus、EWSR1_fus、EXOSC8、EZH2、EZR_fus、F13A1、
FAM149A、FAM153B、FAM46C、FANCA、FANCC、FANCD2、FANCG、FANCI、FAS、FAT1、FBXW7、FGF16、
FGF19、FGF3、FGF4、FGFR1、FGFR2、FGFR2_fus、FGFR3、FGFR4、FH、FLCN、FLOT1、FLT1、FLT3、
FLT4、FMO1、FOLH1、FOXL2、FOXP1、FRAS1、FUBP1、FUS_fus、GABRP、GANC、GATA1、GATA2、GATA3、
GLI1、GMEB1、GNA11、GNA13、GNAQ、GNAS、GPM6A、GRIN2A、GSK3B、GSTM1、H3F3A、HAUS2、HCAR2、
HEY1_fus、HGF、HLA-A、HLA-B、HLA-C、HNF1A、HNRNPH1、HRAS、HSPA1B、HSPA4、HYOU1、IARS、
ID2、ID3、IDH1、IDH2、IGF1R、IGF2、IKBKE、IKZF1、IL7R、IL8、INHBA、INPP4B、IPO7、IRAK1、
IRF4、IRF6、IRF8、IRS2、ITGAL、JAK1、JAK2、JAK3、JUN、KCNJ2、KDM5A、KDM5C、KDM6A、KDR、
KEAP1、KIAA1210、KIAA1432、KIF5B_fus、KIR3DX1、KIT、KMT2A、KMT2C、KMT2D、KPNA4、KPNB1、
KRAS、LAMA3、LEPR、LMO1、LOC100131626、LONRF3、LRRC34、LYN、MAGOHB、MALT1、MAP2K1、
MAP2K2、MAP2K4、MAP3K1、MAP3K4、MAP4K5、MAPK1、MAPKAP1、MARK2、MCL1、MDM2、MDM4、MED12、
MED19、MEF2B、MEIS1、MEN1、MET、MIR1273H、MITF、MLH1、MMP16、MONO-27、MOV10L1、MPL、
MRE11A、MRPL19、MSH2、MSH3、MSH6、MTF1、MTOR、MTRR、MUTYH、MYADM、MYC、MYCL、MYCN、MYD88、
MYO10、NAB1、NAB2_fus、NBN、NCOA6、NDUFS1、NEO1、NF1、NF2、NFE2L2、NFKBIA、NFXL1、NKX2-1、
NOTCH1、NOTCH2、NOTCH3、NPM1、NR-21、NR-24、NR4A3_fus、NRAS、NSD1、NT5C2、NTRK1、NTRK1_
fus、NTRK2、NTRK2_fus、NTRK3、NTRK3_fus、NUP85、NUP93、P2RY8、PALB2、PAPOLG、PAQR8、
PARK2、PARP1、PAX5、PBRM1、PDCD1、PDCD1LG2、PDE6C、PDGFB_fus、PDGFRA、PDGFRB、PDPN、
PIGF、PIK3C2G、PIK3CA、PIK3CB、PIK3CG、PIK3R1、PIK3R2、PLCG2、PLEKHA1、PLEKHH2、PMS2、
PNO1、POLD1、POLE、PPARG、PPHLN1_fus、PPP2R1A、PRDM1、PREX2、PRKAR1A、PRKCI、PRPF39、
PTCH1、PTEN、PTPN11、PTPRJ、PURA、RABGAP1L、RAC1、RAD21、RAD50、RAD51、RAD51B、RAD51C、
RAD51D、RAD52、RAD54L、RAF1、RARA、RB1、RBM10、RBM27、REL、RET、RET_fus、RHOT1、RICTOR、
RIPK2、RNF19A、RNF43、ROS1、ROS1_fus、RPA4、RPTOR、RRP1B、RUNX1、RYR2、SASH1、SDHA、SDHB、
SDHC、SDHD、SEL1L3、SETD2、SF3B1、SHROOM3、SIPA1L2、SLC34A2_fus、SMAD2、SMAD3、SMAD4、
SMARCA4、SMARCB1、SMO、SNX6、SOCS1、SOX2、SOX9、SPC24、SPEN、SPOP、SRC、SS18_fus、STAG2、
STAT3、STK11、STMN1、STRBP、SUCLG1、SUFU、SUGCT、SYK、TAF15、TAGAP、TBC1D8B、TBX3、
TECPR2、TERT、TET2、TGFBR2、TMEM67、TMPRSS15、TMPRSS2、TNFAIP3、TNFRSF14、TNFSF13B、
TNKS、TNRC18、TOP1、TOP2B、TP53、TPH1、TRA2A、TRIM24、TSC1、TSC2、TSHR、TSN、TXNRD1、
U2AF1、UBE2E3、UBE3C、ULK4、UPF2、UTY、VEGFA、VHL、VSIG10、WHSC1、WHSC1L1、WT1、WWC3、
XPO1, ZBBX, ZDHHC17, ZNF711, ZNF805 and ZZZ3.
Further, microsatellite instability site include rs1045642, rs1052555, rs10981694,
rs11045585、rs1105525、rs1130214、rs1138272、rs115232898、rs11572080、rs11598702、
rs11615、rs12613732、rs12762549、rs13181、rs151264360、rs1517114、rs1570360、
rs1650697、rs1650723、rs1695、rs1799793、rs1801019、rs1801131、rs1801133、rs1801265、
rs1805087、rs183484、rs1934951、rs2032582、rs2072671、rs2075252、rs2228001、
rs2273618、rs2291075、rs2291767、rs2297595、rs2494752、rs2501873、rs25487、
rs2784917、rs28738963、rs316019、rs3212986、rs3745274、rs3892097、rs3918290、
rs3957357、rs4148323、rs4244285、rs430397、rs442767、rs4646、rs4673、rs4673993、
rs4728709、rs4880、rs50872、rs55886062、rs60369023、rs67376798、rs699947、rs716274、
Rs7779029, rs7851395, rs8133052, rs8175347, rs873478, rs9679162 and rs9937.
According to another aspect of the present invention, provide it is a kind of based on the sequencing of two generations for the targeting of general cancer kind, chemotherapy and exempt from
The detection kit of epidemic disease medication.The detection kit includes detection probe, and detection probe is directed to general cancer kind parting, treatment, prognosis
Relevant gene mutation, microsatellite instability site and the relevant exon region of Tumor mutations carry calculation.
Further, detection probe overlay area/target area >=99%.
Further, general cancer kind parting, treatment, the relevant gene mutation of prognosis and Tumor mutations carry calculation are relevant outer
Aobvious subregion include: ABCA13, ABCA8, ABL1, ACADSB, ACOT13, ADAMTS6, ADRB1, ADSS, AGPAT9, AK7,
AKT1、AKT2、AKT3、ALG9、ALK、ALK_fus、ALOX12B、ALS2CR11、AMER1、ANKRA2、ANKRD46、ANO1、
APC、APOPT1、AR、ARAF、ARHGAP4、ARHGAP6、ARID1A、ARID1B、ARID2、ARID4A、ARL6IP6、ARMC5、
ARPC2、ASH1L、ASXL1、ATM、ATP9B、ATR、ATRX、AURKA、AURKB、AXIN1、AXL、B2M、BAP1、BARD1、
BAT-25、BAT-26、BCL2、BCL2L1、BCOR、BCYRN1、BLM、BRAF、BRCA1、BRCA2、BRD4、BRIP1、BRS3、
BTF3、BTG1、BTK、C20orf96、C22orf23、C5orf42、C9orf72、CAB39、CALD1、CALM2、CALR、
CARD11、CASP8、CAST,ERAP1、CBFB、CBL、CBR4、CCND1、CCND2、CCND3、CCNE1、CCR4、CD274、
CD40、CD74_fus、CD79A、CD79B、CDC25B、CDC73、CDH1、CDK12、CDK4、CDK6、CDK7、CDK8、CDKL3、
CDKN1A、CDKN1B、CDKN2A、CDKN2B、CDKN2C、CDO1、CEBPA、CEP120、CHD1、CHEK1、CHEK2、CIC、
CNKSR3、CNOT8、COSM1316144、COSM1316145、COSM1332498、COSM3676668、COSM3747491、
COSM5045664、COX18、CREBBP、CRKL、CRLF2、CSF1R、CSF3R、CTAGE5、CTCF、CTNNB1、CUL3、
CXCR4、CYFIP1、CYLD、DAXX、DBT、DDR2、DEPDC5、DIAPH1、DICER1、DIS3、DNMT3A、DOCK11、
DOT1L、DROSHA、DSCAM、DXS6804、DXS7132、DXS7423、DYS391、DYS438、DYS458、EGFR、EGFR_
fus、EIF4G3、EML4_fus、EP300、EPHA3、EPHA5、EPHA7、EPHB1、ERBB2、ERBB3、ERBB4、ERCC4、
ERG、ERI1、ERRFI1、ESR1、ETV1、ETV6、ETV6_fus、EWSR1_fus、EXOSC8、EZH2、EZR_fus、F13A1、
FAM149A、FAM153B、FAM46C、FANCA、FANCC、FANCD2、FANCG、FANCI、FAS、FAT1、FBXW7、FGF16、
FGF19、FGF3、FGF4、FGFR1、FGFR2、FGFR2_fus、FGFR3、FGFR4、FH、FLCN、FLOT1、FLT1、FLT3、
FLT4、FMO1、FOLH1、FOXL2、FOXP1、FRAS1、FUBP1、FUS_fus、GABRP、GANC、GATA1、GATA2、GATA3、
GLI1、GMEB1、GNA11、GNA13、GNAQ、GNAS、GPM6A、GRIN2A、GSK3B、GSTM1、H3F3A、HAUS2、HCAR2、
HEY1_fus、HGF、HLA-A、HLA-B、HLA-C、HNF1A、HNRNPH1、HRAS、HSPA1B、HSPA4、HYOU1、IARS、
ID2、ID3、IDH1、IDH2、IGF1R、IGF2、IKBKE、IKZF1、IL7R、IL8、INHBA、INPP4B、IPO7、IRAK1、
IRF4、IRF6、IRF8、IRS2、ITGAL、JAK1、JAK2、JAK3、JUN、KCNJ2、KDM5A、KDM5C、KDM6A、KDR、
KEAP1、KIAA1210、KIAA1432、KIF5B_fus、KIR3DX1、KIT、KMT2A、KMT2C、KMT2D、KPNA4、KPNB1、
KRAS、LAMA3、LEPR、LMO1、LOC100131626、LONRF3、LRRC34、LYN、MAGOHB、MALT1、MAP2K1、
MAP2K2、MAP2K4、MAP3K1、MAP3K4、MAP4K5、MAPK1、MAPKAP1、MARK2、MCL1、MDM2、MDM4、MED12、
MED19、MEF2B、MEIS1、MEN1、MET、MIR1273H、MITF、MLH1、MMP16、MONO-27、MOV10L1、MPL、
MRE11A、MRPL19、MSH2、MSH3、MSH6、MTF1、MTOR、MTRR、MUTYH、MYADM、MYC、MYCL、MYCN、MYD88、
MYO10、NAB1、NAB2_fus、NBN、NCOA6、NDUFS1、NEO1、NF1、NF2、NFE2L2、NFKBIA、NFXL1、NKX2-1、
NOTCH1、NOTCH2、NOTCH3、NPM1、NR-21、NR-24、NR4A3_fus、NRAS、NSD1、NT5C2、NTRK1、NTRK1_
fus、NTRK2、NTRK2_fus、NTRK3、NTRK3_fus、NUP85、NUP93、P2RY8、PALB2、PAPOLG、PAQR8、
PARK2、PARP1、PAX5、PBRM1、PDCD1、PDCD1LG2、PDE6C、PDGFB_fus、PDGFRA、PDGFRB、PDPN、
PIGF、PIK3C2G、PIK3CA、PIK3CB、PIK3CG、PIK3R1、PIK3R2、PLCG2、PLEKHA1、PLEKHH2、PMS2、
PNO1、POLD1、POLE、PPARG、PPHLN1_fus、PPP2R1A、PRDM1、PREX2、PRKAR1A、PRKCI、PRPF39、
PTCH1、PTEN、PTPN11、PTPRJ、PURA、RABGAP1L、RAC1、RAD21、RAD50、RAD51、RAD51B、RAD51C、
RAD51D、RAD52、RAD54L、RAF1、RARA、RB1、RBM10、RBM27、REL、RET、RET_fus、RHOT1、RICTOR、
RIPK2、RNF19A、RNF43、ROS1、ROS1_fus、RPA4、RPTOR、RRP1B、RUNX1、RYR2、SASH1、SDHA、SDHB、
SDHC、SDHD、SEL1L3、SETD2、SF3B1、SHROOM3、SIPA1L2、SLC34A2_fus、SMAD2、SMAD3、SMAD4、
SMARCA4、SMARCB1、SMO、SNX6、SOCS1、SOX2、SOX9、SPC24、SPEN、SPOP、SRC、SS18_fus、STAG2、
STAT3、STK11、STMN1、STRBP、SUCLG1、SUFU、SUGCT、SYK、TAF15、TAGAP、TBC1D8B、TBX3、
TECPR2、TERT、TET2、TGFBR2、TMEM67、TMPRSS15、TMPRSS2、TNFAIP3、TNFRSF14、TNFSF13B、
TNKS、TNRC18、TOP1、TOP2B、TP53、TPH1、TRA2A、TRIM24、TSC1、TSC2、TSHR、TSN、TXNRD1、
U2AF1、UBE2E3、UBE3C、ULK4、UPF2、UTY、VEGFA、VHL、VSIG10、WHSC1、WHSC1L1、WT1、WWC3、
XPO1, ZBBX, ZDHHC17, ZNF711, ZNF805 and ZZZ3.
Further, microsatellite instability site include rs1045642, rs1052555, rs10981694,
rs11045585、rs1105525、rs1130214、rs1138272、rs115232898、rs11572080、rs11598702、
rs11615、rs12613732、rs12762549、rs13181、rs151264360、rs1517114、rs1570360、
rs1650697、rs1650723、rs1695、rs1799793、rs1801019、rs1801131、rs1801133、rs1801265、
rs1805087、rs183484、rs1934951、rs2032582、rs2072671、rs2075252、rs2228001、
rs2273618、rs2291075、rs2291767、rs2297595、rs2494752、rs2501873、rs25487、
rs2784917、rs28738963、rs316019、rs3212986、rs3745274、rs3892097、rs3918290、
rs3957357、rs4148323、rs4244285、rs430397、rs442767、rs4646、rs4673、rs4673993、
rs4728709、rs4880、rs50872、rs55886062、rs60369023、rs67376798、rs699947、rs716274、
Rs7779029, rs7851395, rs8133052, rs8175347, rs873478, rs9679162 and rs9937.
In accordance with a further aspect of the present invention, provide it is a kind of it is above-mentioned based on the sequencing of two generations for the targeting of general cancer kind, chemotherapy
And the detection for the targeting of general cancer kind, chemotherapy and immune medication that the detection panel or above-mentioned of immune medication is sequenced based on two generations
Kit is used for general cancer kind parting, treatment, the relevant gene mutation of prognosis in preparation, and microsatellite instability site and tumour are prominent
Varying duty calculates the application in the device of relevant exon region joint-detection.
Further, general cancer kind includes but is not limited to: lung cancer, intestinal cancer, gastric cancer, liver cancer, breast cancer and carcinoma of endometrium etc.
Deng.
Further, joint-detection includes the detection of various mutations type, including various mutations type: point mutation, fusion,
Copy number variation, missing and insertion mutation；Preferably, using the adjoint diagnosis for including targeting medicine, chemotherapeutic or immune substance.
The design of detection panel of the invention does not instead of simply sum it up multiple gene regions, passes through design integration
Panel homogeneity is improved in the shared region of different mutation type information, reduces panel overall amount of data, reduces cost.
Detection panel includes that general cancer kind parting, treatment, the relevant gene of prognosis, Tumor mutations carry calculation are relevant outer
Aobvious subregion and microsatellite instability site comprising gene information amount it is big, can preferably carry out joint-detection, apply
In targeting medicine, the available more accurate result of adjoint diagnosis of chemotherapeutic or immune substance.
Detailed description of the invention
The accompanying drawings constituting a part of this application is used to provide further understanding of the present invention, and of the invention shows
Examples and descriptions thereof are used to explain the present invention for meaning property, does not constitute improper limitations of the present invention.In the accompanying drawings:
Fig. 1 shows the detection consistency knot in embodiment 4 about the detection panel (P12) of embodiment 1 and complete outer probe
Fruit figure.
Specific embodiment
It should be noted that in the absence of conflict, the features in the embodiments and the embodiments of the present application can phase
Mutually combination.The present invention will be described in detail below with reference to the accompanying drawings and embodiments.
The mechanism that cancer occurs is extremely complex, and various cancers are even suffered from the patient of identical cancer, cancer is caused to be sent out
Raw molecular mechanism and histopathology access is all not quite similar, even the tumour at the same position, therapeutic effect and method
It should vary with each individual, it is this because people, the various disease treatment method taken by disease are known as " individualized treatment ".Therefore it is controlled in cancer
During treatment, only treating the same disease with different methods varies with each individual, and implements individualized treatment, it is suitable could to be directed to different types of patient selection
Their drug.
With deepening continuously for gene molecule level research, more and more tumour cell signal paths are found, largely
Clinical research shows that amplification/mutation/expression status of the specific gene in access and the validity of targeting, chemotherapeutics are close
It is related.Therefore, amplification/mutation/expression of specific gene in these accesses is clinically detected, can be pointedly every trouble
Person makes a set of most suitable therapeutic scheme to measure, to farthest improve the effective percentage for the treatment of, the poison for reducing drug is secondary
Effect, avoids inappropriate medication from affecting therapic opportunity adversely.
Technology involved in the relevant testing product of cancer currently on the market respectively deposits different advantage and disadvantage, can not
Comprehensive sample to be tested is detected.
In view of this, the present invention is the following technical schemes are provided: typically embodiment there is provided one kind for one kind according to the present invention
The detection panel for the targeting of general cancer kind, chemotherapy and immune medication based on the sequencing of two generations.Detection panel include for into
The general cancer kind parting of row joint-detection, treatment, the relevant gene mutation of prognosis (" gene mutation " herein could also say that with it is general
Cancer kind parting, treatment, the relevant mutated gene of prognosis), the relevant exon region of Tumor mutations carry calculation and microsatellite not
Stability site.
Product in the prior art comprehensively the tissue to general cancer kind and blood sample cannot carry out kinds of tumors change simultaneously
Different joint-detection.Panel and kit of the invention can swell to general cancer kind parting, treatment, the relevant gene mutation of prognosis
Tumor mutational load calculates relevant exon region and microsatellite instability site carries out joint-detection simultaneously.And sample type
Cover tissue and blood.
Panel design of the invention does not sum it up not instead of simply, is selected according to demand the type of detection gene
It selects, avoids the region panel redundancy, reduce the output of priceless Value Data, shorten data analytical cycle, reduce testing cost.
It applying the technical scheme of the present invention, detection panel includes general cancer kind parting, treatment, the relevant gene mutation of prognosis,
The relevant exon region of Tumor mutations carry calculation and microsatellite instability site comprising gene information amount it is big, can
Preferably to carry out joint-detection, the adjoint diagnosis applied to targeting medicine, chemotherapeutic or immune substance is available more accurate
As a result.
Preferably, general cancer kind parting, treatment, the relevant gene mutation of prognosis, Tumor mutations carry calculation are relevant outer aobvious
Subregion include ABCA13, ABCA8, ABL1, ACADSB, ACOT13, ADAMTS6, ADRB1, ADSS, AGPAT9, AK7, AKT1,
AKT2、AKT3、ALG9、ALK、ALK_fus、ALOX12B、ALS2CR11、AMER1、ANKRA2、ANKRD46、ANO1、APC、
APOPT1、AR、ARAF、ARHGAP4、ARHGAP6、ARID1A、ARID1B、ARID2、ARID4A、ARL6IP6、ARMC5、
ARPC2、ASH1L、ASXL1、ATM、ATP9B、ATR、ATRX、AURKA、AURKB、AXIN1、AXL、B2M、BAP1、BARD1、
BAT-25、BAT-26、BCL2、BCL2L1、BCOR、BCYRN1、BLM、BRAF、BRCA1、BRCA2、BRD4、BRIP1、BRS3、
BTF3、BTG1、BTK、C20orf96、C22orf23、C5orf42、C9orf72、CAB39、CALD1、CALM2、CALR、
CARD11、CASP8、CAST,ERAP1、CBFB、CBL、CBR4、CCND1、CCND2、CCND3、CCNE1、CCR4、CD274、
CD40、CD74_fus、CD79A、CD79B、CDC25B、CDC73、CDH1、CDK12、CDK4、CDK6、CDK7、CDK8、CDKL3、
CDKN1A、CDKN1B、CDKN2A、CDKN2B、CDKN2C、CDO1、CEBPA、CEP120、CHD1、CHEK1、CHEK2、CIC、
CNKSR3、CNOT8、COSM1316144、COSM1316145、COSM1332498、COSM3676668、COSM3747491、
COSM5045664、COX18、CREBBP、CRKL、CRLF2、CSF1R、CSF3R、CTAGE5、CTCF、CTNNB1、CUL3、
CXCR4、CYFIP1、CYLD、DAXX、DBT、DDR2、DEPDC5、DIAPH1、DICER1、DIS3、DNMT3A、DOCK11、
DOT1L、DROSHA、DSCAM、DXS6804、DXS7132、DXS7423、DYS391、DYS438、DYS458、EGFR、EGFR_
fus、EIF4G3、EML4_fus、EP300、EPHA3、EPHA5、EPHA7、EPHB1、ERBB2、ERBB3、ERBB4、ERCC4、
ERG、ERI1、ERRFI1、ESR1、ETV1、ETV6、ETV6_fus、EWSR1_fus、EXOSC8、EZH2、EZR_fus、F13A1、
FAM149A、FAM153B、FAM46C、FANCA、FANCC、FANCD2、FANCG、FANCI、FAS、FAT1、FBXW7、FGF16、
FGF19、FGF3、FGF4、FGFR1、FGFR2、FGFR2_fus、FGFR3、FGFR4、FH、FLCN、FLOT1、FLT1、FLT3、
FLT4、FMO1、FOLH1、FOXL2、FOXP1、FRAS1、FUBP1、FUS_fus、GABRP、GANC、GATA1、GATA2、GATA3、
GLI1、GMEB1、GNA11、GNA13、GNAQ、GNAS、GPM6A、GRIN2A、GSK3B、GSTM1、H3F3A、HAUS2、HCAR2、
HEY1_fus、HGF、HLA-A、HLA-B、HLA-C、HNF1A、HNRNPH1、HRAS、HSPA1B、HSPA4、HYOU1、IARS、
ID2、ID3、IDH1、IDH2、IGF1R、IGF2、IKBKE、IKZF1、IL7R、IL8、INHBA、INPP4B、IPO7、IRAK1、
IRF4、IRF6、IRF8、IRS2、ITGAL、JAK1、JAK2、JAK3、JUN、KCNJ2、KDM5A、KDM5C、KDM6A、KDR、
KEAP1、KIAA1210、KIAA1432、KIF5B_fus、KIR3DX1、KIT、KMT2A、KMT2C、KMT2D、KPNA4、KPNB1、
KRAS、LAMA3、LEPR、LMO1、LOC100131626、LONRF3、LRRC34、LYN、MAGOHB、MALT1、MAP2K1、
MAP2K2、MAP2K4、MAP3K1、MAP3K4、MAP4K5、MAPK1、MAPKAP1、MARK2、MCL1、MDM2、MDM4、MED12、
MED19、MEF2B、MEIS1、MEN1、MET、MIR1273H、MITF、MLH1、MMP16、MONO-27、MOV10L1、MPL、
MRE11A、MRPL19、MSH2、MSH3、MSH6、MTF1、MTOR、MTRR、MUTYH、MYADM、MYC、MYCL、MYCN、MYD88、
MYO10、NAB1、NAB2_fus、NBN、NCOA6、NDUFS1、NEO1、NF1、NF2、NFE2L2、NFKBIA、NFXL1、NKX2-1、
NOTCH1、NOTCH2、NOTCH3、NPM1、NR-21、NR-24、NR4A3_fus、NRAS、NSD1、NT5C2、NTRK1、NTRK1_
fus、NTRK2、NTRK2_fus、NTRK3、NTRK3_fus、NUP85、NUP93、P2RY8、PALB2、PAPOLG、PAQR8、
PARK2、PARP1、PAX5、PBRM1、PDCD1、PDCD1LG2、PDE6C、PDGFB_fus、PDGFRA、PDGFRB、PDPN、
PIGF、PIK3C2G、PIK3CA、PIK3CB、PIK3CG、PIK3R1、PIK3R2、PLCG2、PLEKHA1、PLEKHH2、PMS2、
PNO1、POLD1、POLE、PPARG、PPHLN1_fus、PPP2R1A、PRDM1、PREX2、PRKAR1A、PRKCI、PRPF39、
PTCH1、PTEN、PTPN11、PTPRJ、PURA、RABGAP1L、RAC1、RAD21、RAD50、RAD51、RAD51B、RAD51C、
RAD51D、RAD52、RAD54L、RAF1、RARA、RB1、RBM10、RBM27、REL、RET、RET_fus、RHOT1、RICTOR、
RIPK2、RNF19A、RNF43、ROS1、ROS1_fus、RPA4、RPTOR、RRP1B、RUNX1、RYR2、SASH1、SDHA、SDHB、
SDHC、SDHD、SEL1L3、SETD2、SF3B1、SHROOM3、SIPA1L2、SLC34A2_fus、SMAD2、SMAD3、SMAD4、
SMARCA4、SMARCB1、SMO、SNX6、SOCS1、SOX2、SOX9、SPC24、SPEN、SPOP、SRC、SS18_fus、STAG2、
STAT3、STK11、STMN1、STRBP、SUCLG1、SUFU、SUGCT、SYK、TAF15、TAGAP、TBC1D8B、TBX3、
TECPR2、TERT、TET2、TGFBR2、TMEM67、TMPRSS15、TMPRSS2、TNFAIP3、TNFRSF14、TNFSF13B、
TNKS、TNRC18、TOP1、TOP2B、TP53、TPH1、TRA2A、TRIM24、TSC1、TSC2、TSHR、TSN、TXNRD1、
U2AF1、UBE2E3、UBE3C、ULK4、UPF2、UTY、VEGFA、VHL、VSIG10、WHSC1、WHSC1L1、WT1、WWC3、
XPO1, ZBBX, ZDHHC17, ZNF711, ZNF805 and ZZZ3.Said gene joint-detection can make general cancer kind parting, treatment,
The detection of the relevant gene mutation of prognosis, the relevant exon region of Tumor mutations carry calculation is more accurate.
Preferably, microsatellite instability site include rs1045642, rs1052555, rs10981694,
rs11045585、rs1105525、rs1130214、rs1138272、rs115232898、rs11572080、rs11598702、
rs11615、rs12613732、rs12762549、rs13181、rs151264360、rs1517114、rs1570360、
rs1650697、rs1650723、rs1695、rs1799793、rs1801019、rs1801131、rs1801133、rs1801265、
rs1805087、rs183484、rs1934951、rs2032582、rs2072671、rs2075252、rs2228001、
rs2273618、rs2291075、rs2291767、rs2297595、rs2494752、rs2501873、rs25487、
rs2784917、rs28738963、rs316019、rs3212986、rs3745274、rs3892097、rs3918290、
rs3957357、rs4148323、rs4244285、rs430397、rs442767、rs4646、rs4673、rs4673993、
rs4728709、rs4880、rs50872、rs55886062、rs60369023、rs67376798、rs699947、rs716274、
Rs7779029, rs7851395, rs8133052, rs8175347, rs873478, rs9679162 and rs9937.It can be further
It is abundant to detect obtained effective information, improve the accuracy of follow-up data application.
According to another aspect of the present invention, provide it is a kind of based on the sequencing of two generations for the targeting of general cancer kind, chemotherapy and exempt from
The detection kit of epidemic disease medication.The detection kit includes detection probe, and detection probe is directed to general cancer kind parting, treatment, prognosis
Relevant gene, microsatellite instability site and the relevant exon region of Tumor mutations carry calculation.Preferably, detection is visited
Needle overlay area/target area >=99%.
A kind of typical embodiment according to the present invention, general cancer kind parting, treatment, the relevant gene mutation of prognosis and tumour
Mutational load calculate relevant exon region include: ABCA13, ABCA8, ABL1, ACADSB, ACOT13, ADAMTS6,
ADRB1、ADSS、AGPAT9、AK7、AKT1、AKT2、AKT3、ALG9、ALK、ALK_fus、ALOX12B、ALS2CR11、AMER1、
ANKRA2、ANKRD46、ANO1、APC、APOPT1、AR、ARAF、ARHGAP4、ARHGAP6、ARID1A、ARID1B、ARID2、
ARID4A、ARL6IP6、ARMC5、ARPC2、ASH1L、ASXL1、ATM、ATP9B、ATR、ATRX、AURKA、AURKB、AXIN1、
AXL、B2M、BAP1、BARD1、BAT-25、BAT-26、BCL2、BCL2L1、BCOR、BCYRN1、BLM、BRAF、BRCA1、
BRCA2、BRD4、BRIP1、BRS3、BTF3、BTG1、BTK、C20orf96、C22orf23、C5orf42、C9orf72、CAB39、
CALD1、CALM2、CALR、CARD11、CASP8、CAST,ERAP1、CBFB、CBL、CBR4、CCND1、CCND2、CCND3、
CCNE1、CCR4、CD274、CD40、CD74_fus、CD79A、CD79B、CDC25B、CDC73、CDH1、CDK12、CDK4、CDK6、
CDK7、CDK8、CDKL3、CDKN1A、CDKN1B、CDKN2A、CDKN2B、CDKN2C、CDO1、CEBPA、CEP120、CHD1、
CHEK1、CHEK2、CIC、CNKSR3、CNOT8、COSM1316144、COSM1316145、COSM1332498、COSM3676668、
COSM3747491、COSM5045664、COX18、CREBBP、CRKL、CRLF2、CSF1R、CSF3R、CTAGE5、CTCF、
CTNNB1、CUL3、CXCR4、CYFIP1、CYLD、DAXX、DBT、DDR2、DEPDC5、DIAPH1、DICER1、DIS3、DNMT3A、
DOCK11、DOT1L、DROSHA、DSCAM、DXS6804、DXS7132、DXS7423、DYS391、DYS438、DYS458、EGFR、
EGFR_fus、EIF4G3、EML4_fus、EP300、EPHA3、EPHA5、EPHA7、EPHB1、ERBB2、ERBB3、ERBB4、
ERCC4、ERG、ERI1、ERRFI1、ESR1、ETV1、ETV6、ETV6_fus、EWSR1_fus、EXOSC8、EZH2、EZR_fus、
F13A1、FAM149A、FAM153B、FAM46C、FANCA、FANCC、FANCD2、FANCG、FANCI、FAS、FAT1、FBXW7、
FGF16、FGF19、FGF3、FGF4、FGFR1、FGFR2、FGFR2_fus、FGFR3、FGFR4、FH、FLCN、FLOT1、FLT1、
FLT3、FLT4、FMO1、FOLH1、FOXL2、FOXP1、FRAS1、FUBP1、FUS_fus、GABRP、GANC、GATA1、GATA2、
GATA3、GLI1、GMEB1、GNA11、GNA13、GNAQ、GNAS、GPM6A、GRIN2A、GSK3B、GSTM1、H3F3A、HAUS2、
HCAR2、HEY1_fus、HGF、HLA-A、HLA-B、HLA-C、HNF1A、HNRNPH1、HRAS、HSPA1B、HSPA4、HYOU1、
IARS、ID2、ID3、IDH1、IDH2、IGF1R、IGF2、IKBKE、IKZF1、IL7R、IL8、INHBA、INPP4B、IPO7、
IRAK1、IRF4、IRF6、IRF8、IRS2、ITGAL、JAK1、JAK2、JAK3、JUN、KCNJ2、KDM5A、KDM5C、KDM6A、
KDR、KEAP1、KIAA1210、KIAA1432、KIF5B_fus、KIR3DX1、KIT、KMT2A、KMT2C、KMT2D、KPNA4、
KPNB1、KRAS、LAMA3、LEPR、LMO1、LOC100131626、LONRF3、LRRC34、LYN、MAGOHB、MALT1、
MAP2K1、MAP2K2、MAP2K4、MAP3K1、MAP3K4、MAP4K5、MAPK1、MAPKAP1、MARK2、MCL1、MDM2、MDM4、
MED12、MED19、MEF2B、MEIS1、MEN1、MET、MIR1273H、MITF、MLH1、MMP16、MONO-27、MOV10L1、
MPL、MRE11A、MRPL19、MSH2、MSH3、MSH6、MTF1、MTOR、MTRR、MUTYH、MYADM、MYC、MYCL、MYCN、
MYD88、MYO10、NAB1、NAB2_fus、NBN、NCOA6、NDUFS1、NEO1、NF1、NF2、NFE2L2、NFKBIA、NFXL1、
NKX2-1、NOTCH1、NOTCH2、NOTCH3、NPM1、NR-21、NR-24、NR4A3_fus、NRAS、NSD1、NT5C2、NTRK1、
NTRK1_fus、NTRK2、NTRK2_fus、NTRK3、NTRK3_fus、NUP85、NUP93、P2RY8、PALB2、PAPOLG、
PAQR8、PARK2、PARP1、PAX5、PBRM1、PDCD1、PDCD1LG2、PDE6C、PDGFB_fus、PDGFRA、PDGFRB、
PDPN、PIGF、PIK3C2G、PIK3CA、PIK3CB、PIK3CG、PIK3R1、PIK3R2、PLCG2、PLEKHA1、PLEKHH2、
PMS2、PNO1、POLD1、POLE、PPARG、PPHLN1_fus、PPP2R1A、PRDM1、PREX2、PRKAR1A、PRKCI、
PRPF39、PTCH1、PTEN、PTPN11、PTPRJ、PURA、RABGAP1L、RAC1、RAD21、RAD50、RAD51、RAD51B、
RAD51C、RAD51D、RAD52、RAD54L、RAF1、RARA、RB1、RBM10、RBM27、REL、RET、RET_fus、RHOT1、
RICTOR、RIPK2、RNF19A、RNF43、ROS1、ROS1_fus、RPA4、RPTOR、RRP1B、RUNX1、RYR2、SASH1、
SDHA、SDHB、SDHC、SDHD、SEL1L3、SETD2、SF3B1、SHROOM3、SIPA1L2、SLC34A2_fus、SMAD2、
SMAD3、SMAD4、SMARCA4、SMARCB1、SMO、SNX6、SOCS1、SOX2、SOX9、SPC24、SPEN、SPOP、SRC、
SS18_fus、STAG2、STAT3、STK11、STMN1、STRBP、SUCLG1、SUFU、SUGCT、SYK、TAF15、TAGAP、
TBC1D8B、TBX3、TECPR2、TERT、TET2、TGFBR2、TMEM67、TMPRSS15、TMPRSS2、TNFAIP3、
TNFRSF14、TNFSF13B、TNKS、TNRC18、TOP1、TOP2B、TP53、TPH1、TRA2A、TRIM24、TSC1、TSC2、
TSHR、TSN、TXNRD1、U2AF1、UBE2E3、UBE3C、ULK4、UPF2、UTY、VEGFA、VHL、VSIG10、WHSC1、
WHSC1L1, WT1, WWC3, XPO1, ZBBX, ZDHHC17, ZNF711, ZNF805 and ZZZ3.
A kind of typical embodiment according to the present invention, microsatellite instability site include rs1045642,
rs1052555、rs10981694、rs11045585、rs1105525、rs1130214、rs1138272、rs115232898、
rs11572080、rs11598702、rs11615、rs12613732、rs12762549、rs13181、rs151264360、
rs1517114、rs1570360、rs1650697、rs1650723、rs1695、rs1799793、rs1801019、rs1801131、
rs1801133、rs1801265、rs1805087、rs183484、rs1934951、rs2032582、rs2072671、
rs2075252、rs2228001、rs2273618、rs2291075、rs2291767、rs2297595、rs2494752、
rs2501873、rs25487、rs2784917、rs28738963、rs316019、rs3212986、rs3745274、
rs3892097、rs3918290、rs3957357、rs4148323、rs4244285、rs430397、rs442767、rs4646、
rs4673、rs4673993、rs4728709、rs4880、rs50872、rs55886062、rs60369023、rs67376798、
rs699947、rs716274、rs7779029、rs7851395、rs8133052、rs8175347、rs873478、rs9679162
And rs9937.
It is a kind of according to the present invention typically above-mentioned general cancer kind target to be used for based on the sequencing of two generations embodiment there is provided a kind of
To, chemotherapy and the detection panel or above-mentioned of immune medication based on two generations be sequenced for the targeting of general cancer kind, chemotherapy and immune medication
Detection kit preparation be used for general cancer kind parting, treatment, the relevant gene mutation of prognosis, microsatellite instability site and
Application in the device of the relevant exon region joint-detection of Tumor mutations carry calculation.Typically, general cancer kind includes but not
It is limited to: lung cancer, intestinal cancer, gastric cancer, liver cancer, breast cancer and carcinoma of endometrium etc..Joint-detection may include various mutations type
Detection, comprising: point mutation, fusion, copy number variation, missing and insertion mutation；Preferably, using including targeting medicine, chemotherapeutic
Or the adjoint diagnosis of immune substance.
Beneficial effects of the present invention are further illustrated below in conjunction with embodiment.
Embodiment 1
The panel of the present embodiment includes general cancer kind parting, treatment, the relevant gene mutation of prognosis, microsatellite instability
Site and the relevant exon region of Tumor mutations carry calculation.Corresponding, the kit of the present embodiment includes detection probe, inspection
Probing needle is directed to general cancer kind parting, treatment, the relevant gene mutation of prognosis, microsatellite instability site and Tumor mutations load
Calculate relevant exon region, detection probe overlay area/target area >=99%.Detection probe is according to the normal of this field
Rule design rule designs.
Wherein, general cancer kind parting, treatment, the relevant gene mutation of prognosis and the relevant exon of Tumor mutations carry calculation
Region include: ABCA13, ABCA8, ABL1, ACADSB, ACOT13, ADAMTS6, ADRB1, ADSS, AGPAT9, AK7, AKT1,
AKT2、AKT3、ALG9、ALK、ALK_fus、ALOX12B、ALS2CR11、AMER1、ANKRA2、ANKRD46、ANO1、APC、
APOPT1、AR、ARAF、ARHGAP4、ARHGAP6、ARID1A、ARID1B、ARID2、ARID4A、ARL6IP6、ARMC5、
ARPC2、ASH1L、ASXL1、ATM、ATP9B、ATR、ATRX、AURKA、AURKB、AXIN1、AXL、B2M、BAP1、BARD1、
BAT-25、BAT-26、BCL2、BCL2L1、BCOR、BCYRN1、BLM、BRAF、BRCA1、BRCA2、BRD4、BRIP1、BRS3、
BTF3、BTG1、BTK、C20orf96、C22orf23、C5orf42、C9orf72、CAB39、CALD1、CALM2、CALR、
CARD11、CASP8、CAST,ERAP1、CBFB、CBL、CBR4、CCND1、CCND2、CCND3、CCNE1、CCR4、CD274、
CD40、CD74_fus、CD79A、CD79B、CDC25B、CDC73、CDH1、CDK12、CDK4、CDK6、CDK7、CDK8、CDKL3、
CDKN1A、CDKN1B、CDKN2A、CDKN2B、CDKN2C、CDO1、CEBPA、CEP120、CHD1、CHEK1、CHEK2、CIC、
CNKSR3、CNOT8、COSM1316144、COSM1316145、COSM1332498、COSM3676668、COSM3747491、
COSM5045664、COX18、CREBBP、CRKL、CRLF2、CSF1R、CSF3R、CTAGE5、CTCF、CTNNB1、CUL3、
CXCR4、CYFIP1、CYLD、DAXX、DBT、DDR2、DEPDC5、DIAPH1、DICER1、DIS3、DNMT3A、DOCK11、
DOT1L、DROSHA、DSCAM、DXS6804、DXS7132、DXS7423、DYS391、DYS438、DYS458、EGFR、EGFR_
fus、EIF4G3、EML4_fus、EP300、EPHA3、EPHA5、EPHA7、EPHB1、ERBB2、ERBB3、ERBB4、ERCC4、
ERG、ERI1、ERRFI1、ESR1、ETV1、ETV6、ETV6_fus、EWSR1_fus、EXOSC8、EZH2、EZR_fus、F13A1、
FAM149A、FAM153B、FAM46C、FANCA、FANCC、FANCD2、FANCG、FANCI、FAS、FAT1、FBXW7、FGF16、
FGF19、FGF3、FGF4、FGFR1、FGFR2、FGFR2_fus、FGFR3、FGFR4、FH、FLCN、FLOT1、FLT1、FLT3、
FLT4、FMO1、FOLH1、FOXL2、FOXP1、FRAS1、FUBP1、FUS_fus、GABRP、GANC、GATA1、GATA2、GATA3、
GLI1、GMEB1、GNA11、GNA13、GNAQ、GNAS、GPM6A、GRIN2A、GSK3B、GSTM1、H3F3A、HAUS2、HCAR2、
HEY1_fus、HGF、HLA-A、HLA-B、HLA-C、HNF1A、HNRNPH1、HRAS、HSPA1B、HSPA4、HYOU1、IARS、
ID2、ID3、IDH1、IDH2、IGF1R、IGF2、IKBKE、IKZF1、IL7R、IL8、INHBA、INPP4B、IPO7、IRAK1、
IRF4、IRF6、IRF8、IRS2、ITGAL、JAK1、JAK2、JAK3、JUN、KCNJ2、KDM5A、KDM5C、KDM6A、KDR、
KEAP1、KIAA1210、KIAA1432、KIF5B_fus、KIR3DX1、KIT、KMT2A、KMT2C、KMT2D、KPNA4、KPNB1、
KRAS、LAMA3、LEPR、LMO1、LOC100131626、LONRF3、LRRC34、LYN、MAGOHB、MALT1、MAP2K1、
MAP2K2、MAP2K4、MAP3K1、MAP3K4、MAP4K5、MAPK1、MAPKAP1、MARK2、MCL1、MDM2、MDM4、MED12、
MED19、MEF2B、MEIS1、MEN1、MET、MIR1273H、MITF、MLH1、MMP16、MONO-27、MOV10L1、MPL、
MRE11A、MRPL19、MSH2、MSH3、MSH6、MTF1、MTOR、MTRR、MUTYH、MYADM、MYC、MYCL、MYCN、MYD88、
MYO10、NAB1、NAB2_fus、NBN、NCOA6、NDUFS1、NEO1、NF1、NF2、NFE2L2、NFKBIA、NFXL1、NKX2-1、
NOTCH1、NOTCH2、NOTCH3、NPM1、NR-21、NR-24、NR4A3_fus、NRAS、NSD1、NT5C2、NTRK1、NTRK1_
fus、NTRK2、NTRK2_fus、NTRK3、NTRK3_fus、NUP85、NUP93、P2RY8、PALB2、PAPOLG、PAQR8、
PARK2、PARP1、PAX5、PBRM1、PDCD1、PDCD1LG2、PDE6C、PDGFB_fus、PDGFRA、PDGFRB、PDPN、
PIGF、PIK3C2G、PIK3CA、PIK3CB、PIK3CG、PIK3R1、PIK3R2、PLCG2、PLEKHA1、PLEKHH2、PMS2、
PNO1、POLD1、POLE、PPARG、PPHLN1_fus、PPP2R1A、PRDM1、PREX2、PRKAR1A、PRKCI、PRPF39、
PTCH1、PTEN、PTPN11、PTPRJ、PURA、RABGAP1L、RAC1、RAD21、RAD50、RAD51、RAD51B、RAD51C、
RAD51D、RAD52、RAD54L、RAF1、RARA、RB1、RBM10、RBM27、REL、RET、RET_fus、RHOT1、RICTOR、
RIPK2、RNF19A、RNF43、ROS1、ROS1_fus、RPA4、RPTOR、RRP1B、RUNX1、RYR2、SASH1、SDHA、SDHB、
SDHC、SDHD、SEL1L3、SETD2、SF3B1、SHROOM3、SIPA1L2、SLC34A2_fus、SMAD2、SMAD3、SMAD4、
SMARCA4、SMARCB1、SMO、SNX6、SOCS1、SOX2、SOX9、SPC24、SPEN、SPOP、SRC、SS18_fus、STAG2、
STAT3、STK11、STMN1、STRBP、SUCLG1、SUFU、SUGCT、SYK、TAF15、TAGAP、TBC1D8B、TBX3、
TECPR2、TERT、TET2、TGFBR2、TMEM67、TMPRSS15、TMPRSS2、TNFAIP3、TNFRSF14、TNFSF13B、
TNKS、TNRC18、TOP1、TOP2B、TP53、TPH1、TRA2A、TRIM24、TSC1、TSC2、TSHR、TSN、TXNRD1、
U2AF1、UBE2E3、UBE3C、ULK4、UPF2、UTY、VEGFA、VHL、VSIG10、WHSC1、WHSC1L1、WT1、WWC3、
XPO1, ZBBX, ZDHHC17, ZNF711, ZNF805 and ZZZ3.
Microsatellite instability site include rs1045642, rs1052555, rs10981694, rs11045585,
rs1105525、rs1130214、rs1138272、rs115232898、rs11572080、rs11598702、rs11615、
rs12613732、rs12762549、rs13181、rs151264360、rs1517114、rs1570360、rs1650697、
rs1650723、rs1695、rs1799793、rs1801019、rs1801131、rs1801133、rs1801265、rs1805087、
rs183484、rs1934951、rs2032582、rs2072671、rs2075252、rs2228001、rs2273618、
rs2291075、rs2291767、rs2297595、rs2494752、rs2501873、rs25487、rs2784917、
rs28738963、rs316019、rs3212986、rs3745274、rs3892097、rs3918290、rs3957357、
rs4148323、rs4244285、rs430397、rs442767、rs4646、rs4673、rs4673993、rs4728709、
rs4880、rs50872、rs55886062、rs60369023、rs67376798、rs699947、rs716274、rs7779029、
Rs7851395, rs8133052, rs8175347, rs873478, rs9679162 and rs9937.
Embodiment 2
It is detected using standard items of the kit in the present embodiment 1 to simulated tissue DNA.
One, validation criteria product are prepared
By mixing the tumor cell line DNA containing known mutations and wild-type cell system GM12878DNA in proportion, match
Produce 20 kinds of mutation standard items DNA.And the frequency of every kind of mutation in standard items is determined by ddPCR.Tumor cell line DNA such as table
Shown in 1.
Table 1
Two, DNA is interrupted:
DNA is quantified using Qubit 3.0 and dsDNA HS Assay Kit.
Polytetrafluoroethylene wire is cut with the medical scissors after ultraviolet sterilization to the length of 1cm or so, and guarantees to interrupt stick
Length homogeneity it is good, be placed in clean container, ultraviolet sterilization 3~4 hours.After the completion of sterilizing, by the polytetrafluoroethylene (PTFE) of 1cm
Line is put into 96 orifice plates with the tweezers after sterilizing.Each hole is packed into 2 and interrupts stick, after the completion again by 96 orifice plate ultraviolet sterilizations 3~
4 hours.
300ng DNA sample is taken according to qubit quantitative result, 50 μ l is diluted to using TE, is transferred in 96 orifice plates, by tin
Foil paper film is placed on 96 orifice plates, and the alignment of four sides using 180 DEG C of heat-sealing film instrument 5s sealer 2 times, is centrifuged using Microplate centrifuge.
Preset program Peak Power:450, Duty Factor:30, Cycles/Burst:200 are selected,
Treatment time:40s, 3cycles are clicked " Start position ".In Run interface point " Run " button, run journey
Sequence.After the completion of program operation, sample panel is taken out, is centrifuged using Microplate centrifuge, then sample panel is put on specimen holder,
Option program Peak Power:450, Duty Factor:30, Cycles/Burst:200, Treatment time:40s,
4cycles.In Run interface point " Run " button, program is run.After the completion of program operation, sample panel is taken out, micropore is used
The centrifugation of plate centrifuge.1 μ l is taken to carry out quality inspection after interrupting.
Three, library construction
1. end repairs and adds A tail in 3 ' ends:
1.1 take DNA obtained in 50 μ L above-mentioned steps two, the use nuclease-free water polishing less than 50 μ L to 50 μ L, according to
Reaction system is added in the following table 2:
Table 2
| Component | Volume |
| Repair and add A buffer in end | 7μL |
| Repair and add A enzyme in end | 3μL |
| DNA | 50μL |
| Total volume | 60μL |
1.2, which are vortexed, mixes, and micro- centrifugation is placed in PCR instrument, response procedures such as the following table 3:
Table 3
2. jointing:
2.1 connectors prepare: 2.5 μ L of connector adds 2.5ul water to be diluted to 5 μ L.
Corresponding reagent is added into above-mentioned reaction tube in 2.2 accordings to the form below 4:
Table 4
| Component | Volume |
| Water | 5μL |
| Connect buffer | 30μL |
| DNA ligase | 10μL |
| Repair and add A product in end | 60μL |
| Total volume | 110μL |
2.3, which are vortexed, mixes, and micro- centrifugation is placed in PCR instrument, response procedures such as the following table 5:
Table 5
| Step | Temperature | Time |
| Jointing | 20℃ | 30min |
| It terminates | 20℃ | ∞ |
Note: hot lid temperature is 50 DEG C
3. being purified after connection:
3.1 packing Beckman Agencourt AMPure XP magnetic beads are into eight new connecting legs, every 88 μ L of pipe.Previous step
It is 2.3 end after PCR, takes out sample, of short duration centrifugation is transferred in the 88 μ L magnetic bead centrifuge tubes dispensed.
3.2 concussions mix, and are incubated at room temperature 15min, combine DNA sufficiently with magnetic bead.Note: by tight pipe lid when concussion.It is short
Temporarily centrifugation, centrifuge tube is placed on magnetic frame to be clarified to liquid, is discarded supernatant and (is guaranteed that residual volume must not exceed 5 μ L).Note: should not
It is drawn onto magnetic bead.
3.3 addition 200 μ L, 80% ethyl alcohol discard after being incubated for 30sec.It is repeated once 200 μ L, 80% ethyl alcohol cleaning step.
Note: 80% ethyl alcohol matching while using.
3.4 exhaust the residual ethanol of centrifugation bottom of the tube with 10 μ L pipette tips, and drying at room temperature 3-5min to ethyl alcohol volatilizees (just completely
Face sees that the back side, which is seen, have been dried not reflective).Note: magnetic bead overdrying DNA output can be reduced.
3.5 remove centrifuge tube from magnetic frame, and 21 μ L ultrapure waters are added, and concussion mixes.Note: by tight pipe lid when concussion.Room
Temperature is incubated for 5min.
3.6 of short duration centrifugations, centrifuge tube is placed on magnetic frame to be clarified to liquid.Remaining 20 μ L clear liquid is transferred to new PCR
Pipe carries out amplification test in next step.
4. amplified library:
4.1 are added reaction system according to the following table 6:
Table 6
| Component | Volume |
| Thermal starting enzyme | 25μL |
| Primer and reaction buffer mixture | 5μL |
| Connector connection product | 20μL |
| Total volume | 50μL |
4.2, which are vortexed, mixes, and micro- centrifugation is placed in PCR instrument, response procedures such as the following table 7:
Table 7
The acquisition of 5.DNA
5.1 25 μ L Beckman Agencourt AMPure XP magnetic beads of packing are into eight new connecting legs.
After 5.2 to previous step (4.2) PCR, sample is taken out.
5.3 of short duration centrifugations are transferred in the 25 μ L Beckman Agencourt AMPure XP magnetic beads dispensed.
5.4 concussions mix, and are incubated at room temperature 15min, combine DNA sufficiently with magnetic bead.By tight pipe lid when paying attention to shaking.
5.5 of short duration centrifugations, centrifuge tube is placed on magnetic frame to be clarified to liquid, and supernatant is transferred to 25 that another pipe has dispensed
In μ L Beckman Agencourt AMPure XP magnetic bead.Note: not be drawn onto magnetic bead.
5.6 concussions mix, and are incubated at room temperature 15min, combine DNA sufficiently with magnetic bead, by tight pipe lid when paying attention to shaking.
5.7 of short duration centrifugations, centrifuge tube is placed on magnetic frame to be clarified to liquid, abandons supernatant.Note: not be drawn onto magnetic bead.
5.8 addition 200 μ L, 80% ethyl alcohol discard after being incubated for 30sec.Note: 80% ethyl alcohol matching while using.It is repeated once
200 μ L80% ethyl alcohol cleaning steps.
5.9 exhaust the residual ethanol of centrifugation bottom of the tube with 10 μ L pipette tips, and drying at room temperature 3-5min to ethyl alcohol volatilizees (just completely
Face sees that the back side, which is seen, have been dried not reflective).Note: magnetic bead overdrying DNA output can be reduced.
5.10 remove centrifuge tube from magnetic frame, and 40 μ L ultrapure waters are added, and oscillation mixes.
5.11 incubation at room temperature 5min eluted dnas.
5.12 of short duration centrifugations, centrifuge tube is placed on magnetic frame to be clarified to liquid, library is transferred in new centrifuge tube.It protects
It is stored in -20 DEG C.
6. library quality inspection
1 μ L DNA library is taken to detect its concentration with dsDNA HS Assay Kit.
The capture of four, Library hybridizations
Library hybridization capture is carried out using present invention detection panel and hybrid capture reagent, operating process is said according to product
Bright book carries out.
1. taking the equivalent library of 1 μ g of total amount in 1.5mL centrifuge tube, according to the concentration in each library and capture library number
Calculate the volume that each library is added.The volume that library is added is: (1000ng/ captures library number/library concentration) μ L.Upwards
It states and 2.5 μ L closing oligonucleotide is added in system, 5 μ L COT Human DNA are added, concussion mixes, of short duration centrifugation.With envelope
Membrana oralis seals EP pipe, is put into traditional vacuum concentrating instrument and is evaporated (60 DEG C, about 20min~1hr).Pay attention to checking whether to have steamed at any time
It is dry.
2. library hybridizes with probe
2.1 walk upwards containing reaction system shown in the following table 8 is added in the dry powder such as library, are vortexed and mix, of short duration centrifugation is placed in 95
DEG C heating module is denaturalized 10min.
Table 8
| Component | Volume |
| Hybridization buffer | 7.5μL |
| Hybridization enhancers | 3μL |
| Total volume | 10.5μL |
2.2 take out 4.5ul probe, of short duration centrifugation；The of short duration centrifugation of probe is placed in 47 DEG C of PCR instruments, rapidly by denaturation
DNA is transferred in the PCR pipe containing probe from 95 DEG C, and concussion mixes, of short duration centrifugation.It is placed in PCR instrument, 47 DEG C of hybridization, hybridization
Time should be no less than 16hr.
3. library captures
3.1 prepare washing steps liquid, and the preparation method such as following table of a capture required buffer liquid is pressed according to the number of capture
The following table 9 prepares buffer.
Table 9
3.2 prepare capture magnetic bead and washing steps liquid 1 and 4, and capture magnetic bead uses preceding palpus equilibrium at room temperature 30min；Elute work
Make liquid 1 and 4 and uses 47 DEG C of incubation 2hr of preceding palpus.
3.3 each captures dispense 100 μ L and capture magnetic bead, and 100 μ L capture magnetic bead is placed in magnetic frame and is clarified up to liquid, is abandoned
Remove supernatant.200 μ L 1X magnetic bead cleaning solutions are added, concussion mixes.It is placed in magnetic frame to clarify up to liquid, discard supernatant.It is added
200 μ L1X magnetic bead cleaning solutions, concussion mix.It is placed in magnetic frame to clarify up to liquid, discard supernatant.100 μ L 1X magnetic beads are added to wash
Liquid is washed, concussion mixes.It is placed in magnetic frame to clarify up to liquid, discard supernatant.Magnetic bead pretreatment at this time is completed, and is carried out immediately next
Step test.
3.4 are transferred to overnight hybridization liquid is captured in cleaned magnetic bead, and pipettor is blown and beaten ten times.It is placed in PCR instrument
47 DEG C of incubation 45min (PCR is warm, and lid temperature is set as 57 DEG C) shake primary guarantee magnetic bead every 15min and suspend.
3.5 cleanings:
3.5.1 after the completion of being incubated for, 1 × washing steps liquid 1 of 47 DEG C of 100 μ L preheatings is added in every pipe, and concussion mixes.It is placed in
Magnetic frame is clarified up to liquid, is discarded supernatant.
3.5.2 1 × washing steps liquid 4 of 47 DEG C of 200 μ L preheatings is added, pipettor blows and beats ten mixings.47 DEG C of incubations
5min is placed in magnetic frame and clarifies up to liquid, discards supernatant.Notice that operating process avoids temperature lower than 47 DEG C as far as possible.
3.5.3 1 × washing steps liquid 4 of 47 DEG C of 200 μ L preheatings is added, pipettor blows and beats ten mixings.47 DEG C of incubations
5min is placed in magnetic frame and clarifies up to liquid, discards supernatant.Notice that operating process avoids temperature lower than 47 DEG C as far as possible.
3.5.4 1 × washing steps liquid 1 that 200 μ L are placed at room temperature for is added, vibrates 2min, of short duration centrifugation is placed on magnetic frame
It clarifies, discards supernatant to liquid.
3.5.5 1 × washing steps liquid 2 that 200 μ L are placed at room temperature for is added, shakes 1min, of short duration centrifugation is placed on magnetic frame
It clarifies, discards supernatant to liquid.
3.5.6 1 × washing steps liquid 3 that 200 μ L are placed at room temperature for is added, shakes 30sec, magnetic frame is placed in of short duration centrifugation
It clarifies, discards supernatant up to liquid.
3.5.7 the 18 ultrapure water elutions of μ L are added into centrifuge tube, concussion mixes, and carries out amplification test in next step.
4. PCR after capture:
Reaction system is added in 4.1 accordings to the form below 10.
Table 10
| Component | Volume |
| Thermal starting enzyme | 50μL |
| Primer, 5 μM | 10μL |
| The DNA of previous step elution | 40μL |
| Total volume | 100μL |
4.2, which are vortexed, mixes, and micro- centrifugation is placed in PCR instrument, response procedures such as the following table 11:
Table 11
It is purified after 4.3 amplifications:
4.3.1 purifying magnetic bead is taken out, equilibrium at room temperature 30min is spare.
4.3.2 take 180 μ L purifying magnetic bead in 1.5mL centrifuge tube, the capture dna library after 100 μ L amplification is added, oscillation
It mixes, is incubated at room temperature 15min.
4.3.3 it is placed in magnetic frame to clarify up to liquid, discard supernatant.
4.3.4 it is added after 200 μ L, 80% ethyl alcohol is incubated for 30sec and discards.Note: 80% ethyl alcohol matching while using.It is repeated once
200 μ L80% ethyl alcohol cleaning steps.
4.3.5 the residual ethanol of centrifugation bottom of the tube is discarded with 10 μ L pipette tips, drying at room temperature to ethyl alcohol is volatilized completely, and (front is seen
Magnetic bead is non-reflective, and drying is seen at the back side).Note: magnetic bead overdrying DNA output can be reduced.
4.3.6 centrifuge tube is removed from magnetic frame, 50 μ L ultrapure waters is added, oscillation mixes.It is incubated at room temperature 2min.
4.3.7 of short duration centrifugation is placed in magnetic frame and clarifies up to liquid, capture sample is transferred in new centrifuge tube.
4.3.8 quality inspection: take 1 μ L capture sample for Qubit Concentration Testing.Capture Concentration Testing uses Qubit
HS detection kit.
Five, testing results
See Table 1 for details 2 for testing result.
Table 12
According to upper 12 result of table it is found that using ddPCR testing result as goldstandard, the detection panel of embodiment 1 is to tissue sample
This point mutation, insertion and deletion, fusion and copy number variation detection performance it is superior.
Embodiment 3
CfDNA sample is carried out using the kit of the embodiment of the present invention 1 and builds library and capture.
One, validation criteria product are prepared
By mixing the tumor cell line DNA containing known mutations and wild-type cell system GM12878DNA in proportion, match
Produce 20 kinds of mutation standard items DNA.And the frequency of every kind of mutation in standard items is determined by ddPCR.Tumor cell line DNA such as table
Shown in 1.Standard items DNA is interrupted, the fragment length (~165bp) of cfDNA is simulated.
Two, library constructions
1. end repairs and adds A tail in 3 ' ends:
1.1 take 50 μ L cfDNA, the use nuclease-free water polishing less than 50 μ L to 50 μ L, add according to the table 2 in embodiment 2
Enter reaction system.
1.2, which are vortexed, mixes, and micro- centrifugation is placed in PCR instrument, the table 3 in response procedures such as embodiment 2.
2. jointing:
2.1 dilutions connector (connectors that 15 μM of concentration), the use volume of connector is 5 μ L.The preservation concentration of connector is 15 μM,
According to the initial amount of DNA, the use concentration of 13 butt joint of according to the form below is diluted, and dilution is placed on 4 DEG C of refrigerators and saves.
Table 13
| Build library initial amount (ng) | Connector volume (μ L) | Nuclease-Free ddH2O volume (μ L) |
| 25-50 | 5 | 0 |
| 10-25 | 2.5 | 2.5 |
| 5-10 | 1 | 4 |
2.2 are added corresponding reagent into above-mentioned reaction tube by the table 4 in embodiment 2.
2.3, which are vortexed, mixes, and micro- centrifugation is placed in PCR instrument, and response procedures are as shown in the table 5 in embodiment 2.
3. purifying (specific steps referring to purified after the connection in embodiment 2) after connection.
4. amplified library (specific steps are referring to embodiment).
The acquisition (1 × Beads recycling) of 5.DNA
5.1 50 μ L Beckman Agencourt AMPure XP magnetic beads of packing are into eight new connecting legs.
After 5.2 to previous step (4.2) PCR, sample is taken out.
5.3 of short duration centrifugations are transferred in the 50 μ L Beckman Agencourt AMPure XP magnetic beads dispensed.
5.4 concussions mix, and are incubated at room temperature 15min, combine DNA sufficiently with magnetic bead.By tight pipe lid when paying attention to shaking.
5.5 of short duration centrifugations, centrifuge tube is placed on magnetic frame to be clarified to liquid, is discarded supernatant.Note: not be drawn onto magnetic bead.
5.6 addition 200 μ L, 80% ethyl alcohol discard after being incubated for 30sec.Note: 80% ethyl alcohol matching while using.It is repeated once
200 μ L80% ethyl alcohol cleaning steps.
5.7 exhaust the residual ethanol of centrifugation bottom of the tube with 10 μ L pipette tips, and drying at room temperature 3-5min to ethyl alcohol volatilizees (just completely
Face sees that the back side, which is seen, have been dried not reflective).Note: magnetic bead overdrying DNA output can be reduced.
5.8 remove centrifuge tube from magnetic frame, and 40 μ L ultrapure waters are added, and oscillation mixes.
5.9 incubation at room temperature 5min eluted dnas.
5.10 of short duration centrifugations, centrifuge tube is placed on magnetic frame to be clarified to liquid, library is transferred in new centrifuge tube.It protects
It is stored in -20 DEG C.
6. library quality inspection
1 μ L DNA library is taken to detect its concentration with dsDNA HS Assay Kit.
The capture of four, Library hybridizations
Concrete operations are the same as embodiment 2.
Five, testing results
See Table 1 for details 4 for testing result.
Table 14
According to upper table as a result, using ddPCR testing result as goldstandard, the detection kit of embodiment 1 is to cfDNA sample
Point mutation, insertion and deletion, fusion and copy number variation detection performance it is superior.
Embodiment 4
Using the consistency of kit detection the tissue T MB and full exon kit of embodiment 1
1. the extraction of patient gene's group DNA, library preparation and probe hybrid capture
The paired sample that the present embodiment has chosen 40 patients detects, and uses Tiangeng haemocyte and tissue extraction reagent
Box extracts haemocyte, tumour flesh tissue DNA, extracts tumour FFPE DNA, operation using Jena FFPE DNA extraction kit
Process is carried out according to product description.It interrupts according to the progress of embodiment 2 DNA and is prepared with library, the reagent of embodiment 1 is respectively adopted
Box and complete outer probe carry out hybrid capture and the sequencing of upper machine.Sample information is as shown in Table 15:
Table 15
Cancer kind includes: carcinoma of endometrium, low level serous adenocarcinoma, colon and rectum carcinoma, oophoroma, gastric cancer, second shape knot
Intestinal cancer, breast cancer, cholangiocarcinoma, lung cancer, intestinal cancer, gastric cancer and glioma.
2. lower machine data analysis
Calculate TMB formula: in the i.e. every megabasse of the complete outer base number (depth > 100X after duplicate removal) of mutation quantity * 1000000/
The sum of displacement and insertion/deletion mutation occurs
Following situations will exclude TMB and calculate:
(1) germline mutation；
(2) frequency of mutation is lower than 5% mutation；
(3) same sense mutation；
(4) depth is lower than 100X after FFPE sample duplicate removal；
(5) repeat region is mutated；
(6) blacklist is mutated；
(7) driving mutation；
(8) demographic data library genetic mutation site.
3. testing result
The present embodiment has detected the pairing haemocyte and FFPE of 163 patients altogether, it is determined that TMB critical value, critical value knot
Fruit is as shown in table 16:
Table 16
| TMB-Moderate | TMB-High | TMB-Extra High |
| 3.804 | 8.4278 | 13.7693 |
By 16 verification result of table it is found that mutation number, which is greater than 13.7693, TMB level, is judged as Extra High；Mutation
Number is judged as High between 8.4278-13.7693.
The detection panel and full exon probe of embodiment 1 has been respectively adopted in the present embodiment, has detected 40 patients' altogether
Match haemocyte and FFPE, it is determined that the consistency of the detection panel and full exon probe of embodiment 1, consistency result is such as
Shown in Fig. 1.
By Fig. 1 result it is found that the detection panel (P12) of embodiment 1 and the consistency of full exon probe are good, the two one
Cause property R2=0.9411.
The present embodiment is inserted for 20 point mutation of Tumor mutations load (TMB) exon region designed while covering, 4
Enter and merged with 8, by integrating the shared region of different mutation type information, improves panel homogeneity, it is whole to reduce panel
Data volume shortens analytical cycle, reduces cost.
Embodiment 5
The consistency of detection panel the detection MSI and generation method of embodiment 1
1. the extraction of patient gene's group DNA, library preparation and probe hybrid capture
Puncturing tissue, surgical tissue or paraffin section extract DNA, take 200ng DNA to carry out covaris and interrupt, interrupt
Sample afterwards constructs library, and using the 12 hybrid capture library panel, the sample after the completion of capturing is in Illumina NovaSeq
It is sequenced on platform.Processing sequence data are analyzed, which is intended to accurately detect microsatellite instability (MSI).
2. lower machine data analysis
MSI QC standard: depth > 100X after each MSI marker duplicate removal.
Panel MSI of 24 mononucleotide repeating label objects for embodiment 1 is measured.If a sample passes through QC's
Marker quantity is less than 8, then MSI state is QNS.If unstable locus/pass through locus >=0.3, MSI shape
State is HSI-H；If unstable locus/pass through site < 0.3, MSI state as HSI-L/MSS.MSI marker is shown in Table
17。
Table 17
3. testing result
The detection panel of embodiment 1 is detected suitable for MSI, and 140 blood cell samples are selected for MSI marker.It comes from
30 blood cell samples of healthy donors are established for p12MSI baseline.Pass through fluorescence pcr- Capillary Electrophoresis
(MSIAnalysis System, Version 1.2, Promega), 40 clinical tumor tissue MSI states are it is known that this 40
Sample carries out GeneCast Panel 12MSI verifying.Verification result shows there is 14 MSI-High, 25 MSI-Low/MSS
With 1 QNS.Specifying information is shown in Table 18.
Table 18
Table 19
| NGS/PCR | MSI-H_PCR | MSI-L/MSS_PCR |
| MSI-H_NGS | 14 | 0 |
| MSI-L/MSS_NGS | 0 | 25 |
| QNS_NGS | 1 | 0 |
Table 20
| TP | TN | FP | FN | Sensitivity | Specificity |
| 14 | 25 | 0 | 0 | 100% | 100% |
It is total for the MSI verification method and fluorescent PCR-capillary electrophoresis method consistency of the detection panel of embodiment 1
Knot such as table 19 and table 20.Sensitivity is 100%, and specificity is 98.2%, PPV 94.7%, accuracy 98.7%.
Embodiment 6
The consistency of result is commented in the detection panel detection mutation of embodiment 1 with room interstitial
1. Room interstitial comments sample information table as shown in table 21:
Table 21
2. Room interstitial comments the library of sample to prepare and probe hybrid capture
23 samples (14 CF and 9 FFPE) of the present embodiment carry out DNA extraction according to embodiment 2 and embodiment 3, beat
Disconnected (FFPE sample is interrupted, and CF sample does not interrupt), library preparation, probe hybrid capture and the sequencing of upper machine.
3. testing result is shown in Table 22.
Table 22
Continued 22
According to upper table 22 as a result, all mutation have detected, meet verification result.Illustrate that the detection panel of embodiment 1 is quasi-
Exactness is high.
Embodiment 7
Kit energy one-time detection kinds of tumors variation of the invention, testing result is accurate, provides patient and targets medicine, chemotherapy
The medication of medicine and immune substance three classes drug selects, and reduces expense.
The detection adjoint diagnosis of panel clinical application-targeting medicine of embodiment 1.
1. 3 pairing clinical samples of the present embodiment carry out DNA extraction according to embodiment 2 and embodiment 3, interrupt (FFPE
Or flesh tissue sample is interrupted, CF sample does not interrupt), library preparation, probe hybrid capture and upper machine sequencing.
2. testing result is shown in
Table 24
According to upper table 24 as a result, patient's TMB level is LOW, but detect that EGFR gene p.L858R is prominent in tissue DNA
Become, Tarceva, Afatinib, Gefitinib, Conmana, difficult to understand wish are likely to be suited for subject for Buddhist nun.Illustrate embodiment 1
Detection panel can be used for targeting the adjoint diagnosis of medicine.
Embodiment 8
Medication, which is immunized, in the detection panel clinical application-of embodiment 1 the results are shown in Table 25.
1. the clinical sample of the present embodiment carries out DNA extraction according to embodiment 2 and embodiment 3, interrupts (FFPE or fresh groups
Knit sample to be interrupted, CF sample does not interrupt), library preparation, probe hybrid capture and upper machine sequencing.
2. testing result is shown in Table 25 and table 26.
Table 25
According to upper table 25 as a result, EGFR, KRAS, BRAF and ERBB2 etc. are not detected in plasma DNA and tissue DNA
Sensitive and medicament-resistant mutation；The increase of MET gene copy number and sensitivity/medicament-resistant mutation is not detected；ALK, ROS1 and RET is not detected
The fusion such as gene and sensitive and drug resistance site mutation.But patient's TMB level is Extra High, mTORC1/2 inhibitor, thunder
Lu Dankang, necitumumab, Afatinib, peace sieve are not likely to be suited for subject for Buddhist nun.
Table 26
According to upper table 26 as a result, be not detected in plasma DNA and tissue DNA EGFR, KRAS, NRAS, BRAF,
The sensitivity such as PIK3CA, KIT, PDGFRA, MTOR gene and medicament-resistant mutation；The fusion of ALK, ROS1, RET gene and quick is not detected
Sense/medicament-resistant mutation；The increase of ERBB2, MET gene copy number and sensitivity/medicament-resistant mutation is not detected.But patient's TMB level is
Extra High。
2 clinical sample testing results of the present embodiment prove that the detection panel of embodiment 1 can be used in immune medication
Guidance.
The foregoing is only a preferred embodiment of the present invention, is not intended to restrict the invention, for the skill of this field
For art personnel, the invention may be variously modified and varied.All within the spirits and principles of the present invention, made any to repair
Change, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.
Claims (10)
1. a kind of detection panel for the targeting of general cancer kind, chemotherapy and immune medication based on the sequencing of two generations, which is characterized in that
The detection panel includes for carrying out the general cancer kind parting of joint-detection, treatment, the relevant gene mutation of prognosis, and tumour is prominent
Varying duty calculates relevant exon region and microsatellite instability site.
2. detection panel according to claim 1, which is characterized in that the general cancer kind parting, treatment, prognosis are relevant
Gene mutation and the relevant exon region of the Tumor mutations carry calculation include ABCA13, ABCA8, ABL1, ACADSB,
ACOT13、ADAMTS6、ADRB1、ADSS、AGPAT9、AK7、AKT1、AKT2、AKT3、ALG9、ALK、ALK_fus、ALOX12B、
ALS2CR11、AMER1、ANKRA2、ANKRD46、ANO1、APC、APOPT1、AR、ARAF、ARHGAP4、ARHGAP6、ARID1A、
ARID1B、ARID2、ARID4A、ARL6IP6、ARMC5、ARPC2、ASH1L、ASXL1、ATM、ATP9B、ATR、ATRX、AURKA、
AURKB、AXIN1、AXL、B2M、BAP1、BARD1、BAT-25、BAT-26、BCL2、BCL2L1、BCOR、BCYRN1、BLM、
BRAF、BRCA1、BRCA2、BRD4、BRIP1、BRS3、BTF3、BTG1、BTK、C20orf96、C22orf23、C5orf42、
C9orf72、CAB39、CALD1、CALM2、CALR、CARD11、CASP8、CAST,ERAP1、CBFB、CBL、CBR4、CCND1、
CCND2、CCND3、CCNE1、CCR4、CD274、CD40、CD74_fus、CD79A、CD79B、CDC25B、CDC73、CDH1、
CDK12、CDK4、CDK6、CDK7、CDK8、CDKL3、CDKN1A、CDKN1B、CDKN2A、CDKN2B、CDKN2C、CDO1、
CEBPA、CEP120、CHD1、CHEK1、CHEK2、CIC、CNKSR3、CNOT8、COSM1316144、COSM1316145、
COSM1332498、COSM3676668、COSM3747491、COSM5045664、COX18、CREBBP、CRKL、CRLF2、
CSF1R、CSF3R、CTAGE5、CTCF、CTNNB1、CUL3、CXCR4、CYFIP1、CYLD、DAXX、DBT、DDR2、DEPDC5、
DIAPH1、DICER1、DIS3、DNMT3A、DOCK11、DOT1L、DROSHA、DSCAM、DXS6804、DXS7132、DXS7423、
DYS391、DYS438、DYS458、EGFR、EGFR_fus、EIF4G3、EML4_fus、EP300、EPHA3、EPHA5、EPHA7、
EPHB1、ERBB2、ERBB3、ERBB4、ERCC4、ERG、ERI1、ERRFI1、ESR1、ETV1、ETV6、ETV6_fus、EWSR1_
fus、EXOSC8、EZH2、EZR_fus、F13A1、FAM149A、FAM153B、FAM46C、FANCA、FANCC、FANCD2、
FANCG、FANCI、FAS、FAT1、FBXW7、FGF16、FGF19、FGF3、FGF4、FGFR1、FGFR2、FGFR2_fus、FGFR3、
FGFR4、FH、FLCN、FLOT1、FLT1、FLT3、FLT4、FMO1、FOLH1、FOXL2、FOXP1、FRAS1、FUBP1、FUS_
fus、GABRP、GANC、GATA1、GATA2、GATA3、GLI1、GMEB1、GNA11、GNA13、GNAQ、GNAS、GPM6A、
GRIN2A、GSK3B、GSTM1、H3F3A、HAUS2、HCAR2、HEY1_fus、HGF、HLA-A、HLA-B、HLA-C、HNF1A、
HNRNPH1、HRAS、HSPA1B、HSPA4、HYOU1、IARS、ID2、ID3、IDH1、IDH2、IGF1R、IGF2、IKBKE、
IKZF1、IL7R、IL8、INHBA、INPP4B、IPO7、IRAK1、IRF4、IRF6、IRF8、IRS2、ITGAL、JAK1、JAK2、
JAK3、JUN、KCNJ2、KDM5A、KDM5C、KDM6A、KDR、KEAP1、KIAA1210、KIAA1432、KIF5B_fus、
KIR3DX1、KIT、KMT2A、KMT2C、KMT2D、KPNA4、KPNB1、KRAS、LAMA3、LEPR、LMO1、LOC100131626、
LONRF3、LRRC34、LYN、MAGOHB、MALT1、MAP2K1、MAP2K2、MAP2K4、MAP3K1、MAP3K4、MAP4K5、
MAPK1、MAPKAP1、MARK2、MCL1、MDM2、MDM4、MED12、MED19、MEF2B、MEIS1、MEN1、MET、MIR1273H、
MITF、MLH1、MMP16、MONO-27、MOV10L1、MPL、MRE11A、MRPL19、MSH2、MSH3、MSH6、MTF1、MTOR、
MTRR、MUTYH、MYADM、MYC、MYCL、MYCN、MYD88、MYO10、NAB1、NAB2_fus、NBN、NCOA6、NDUFS1、
NEO1、NF1、NF2、NFE2L2、NFKBIA、NFXL1、NKX2-1、NOTCH1、NOTCH2、NOTCH3、NPM1、NR-21、NR-
24、NR4A3_fus、NRAS、NSD1、NT5C2、NTRK1、NTRK1_fus、NTRK2、NTRK2_fus、NTRK3、NTRK3_fus、
NUP85、NUP93、P2RY8、PALB2、PAPOLG、PAQR8、PARK2、PARP1、PAX5、PBRM1、PDCD1、PDCD1LG2、
PDE6C、PDGFB_fus、PDGFRA、PDGFRB、PDPN、PIGF、PIK3C2G、PIK3CA、PIK3CB、PIK3CG、PIK3R1、
PIK3R2、PLCG2、PLEKHA1、PLEKHH2、PMS2、PNO1、POLD1、POLE、PPARG、PPHLN1_fus、PPP2R1A、
PRDM1、PREX2、PRKAR1A、PRKCI、PRPF39、PTCH1、PTEN、PTPN11、PTPRJ、PURA、RABGAP1L、RAC1、
RAD21、RAD50、RAD51、RAD51B、RAD51C、RAD51D、RAD52、RAD54L、RAF1、RARA、RB1、RBM10、
RBM27、REL、RET、RET_fus、RHOT1、RICTOR、RIPK2、RNF19A、RNF43、ROS1、ROS1_fus、RPA4、
RPTOR、RRP1B、RUNX1、RYR2、SASH1、SDHA、SDHB、SDHC、SDHD、SEL1L3、SETD2、SF3B1、SHROOM3、
SIPA1L2、SLC34A2_fus、SMAD2、SMAD3、SMAD4、SMARCA4、SMARCB1、SMO、SNX6、SOCS1、SOX2、
SOX9、SPC24、SPEN、SPOP、SRC、SS18_fus、STAG2、STAT3、STK11、STMN1、STRBP、SUCLG1、SUFU、
SUGCT、SYK、TAF15、TAGAP、TBC1D8B、TBX3、TECPR2、TERT、TET2、TGFBR2、TMEM67、TMPRSS15、
TMPRSS2、TNFAIP3、TNFRSF14、TNFSF13B、TNKS、TNRC18、TOP1、TOP2B、TP53、TPH1、TRA2A、
TRIM24、TSC1、TSC2、TSHR、TSN、TXNRD1、U2AF1、UBE2E3、UBE3C、ULK4、UPF2、UTY、VEGFA、VHL、
VSIG10, WHSC1, WHSC1L1, WT1, WWC3, XPO1, ZBBX, ZDHHC17, ZNF711, ZNF805 and ZZZ3.
3. detection panel according to claim 1, which is characterized in that the microsatellite instability site includes
rs1045642、rs1052555、rs10981694、rs11045585、rs1105525、rs1130214、rs1138272、
rs115232898、rs11572080、rs11598702、rs11615、rs12613732、rs12762549、rs13181、
rs151264360、rs1517114、rs1570360、rs1650697、rs1650723、rs1695、rs1799793、
rs1801019、rs1801131、rs1801133、rs1801265、rs1805087、rs183484、rs1934951、
rs2032582、rs2072671、rs2075252、rs2228001、rs2273618、rs2291075、rs2291767、
rs2297595、rs2494752、rs2501873、rs25487、rs2784917、rs28738963、rs316019、
rs3212986、rs3745274、rs3892097、rs3918290、rs3957357、rs4148323、rs4244285、
rs430397、rs442767、rs4646、rs4673、rs4673993、rs4728709、rs4880、rs50872、
rs55886062、rs60369023、rs67376798、rs699947、rs716274、rs7779029、rs7851395、
Rs8133052, rs8175347, rs873478, rs9679162 and rs9937.
4. a kind of detection kit for the targeting of general cancer kind, chemotherapy and immune medication based on the sequencing of two generations, which is characterized in that
The detection kit includes detection probe, and the detection probe is prominent for general cancer kind parting, treatment, the relevant gene of prognosis
Become, microsatellite instability site and the relevant exon region of Tumor mutations carry calculation.
5. detection kit according to claim 4, which is characterized in that the detection probe overlay area/target area >
=99%.
6. detection kit according to claim 4, which is characterized in that the general cancer kind parting, treatment, prognosis are relevant
Gene mutation and the relevant exon region of the Tumor mutations carry calculation include: ABCA13, ABCA8, ABL1, ACADSB,
ACOT13、ADAMTS6、ADRB1、ADSS、AGPAT9、AK7、AKT1、AKT2、AKT3、ALG9、ALK、ALK_fus、ALOX12B、
ALS2CR11、AMER1、ANKRA2、ANKRD46、ANO1、APC、APOPT1、AR、ARAF、ARHGAP4、ARHGAP6、ARID1A、
ARID1B、ARID2、ARID4A、ARL6IP6、ARMC5、ARPC2、ASH1L、ASXL1、ATM、ATP9B、ATR、ATRX、AURKA、
AURKB、AXIN1、AXL、B2M、BAP1、BARD1、BAT-25、BAT-26、BCL2、BCL2L1、BCOR、BCYRN1、BLM、
BRAF、BRCA1、BRCA2、BRD4、BRIP1、BRS3、BTF3、BTG1、BTK、C20orf96、C22orf23、C5orf42、
C9orf72、CAB39、CALD1、CALM2、CALR、CARD11、CASP8、CAST,ERAP1、CBFB、CBL、CBR4、CCND1、
CCND2、CCND3、CCNE1、CCR4、CD274、CD40、CD74_fus、CD79A、CD79B、CDC25B、CDC73、CDH1、
CDK12、CDK4、CDK6、CDK7、CDK8、CDKL3、CDKN1A、CDKN1B、CDKN2A、CDKN2B、CDKN2C、CDO1、
CEBPA、CEP120、CHD1、CHEK1、CHEK2、CIC、CNKSR3、CNOT8、COSM1316144、COSM1316145、
COSM1332498、COSM3676668、COSM3747491、COSM5045664、COX18、CREBBP、CRKL、CRLF2、
CSF1R、CSF3R、CTAGE5、CTCF、CTNNB1、CUL3、CXCR4、CYFIP1、CYLD、DAXX、DBT、DDR2、DEPDC5、
DIAPH1、DICER1、DIS3、DNMT3A、DOCK11、DOT1L、DROSHA、DSCAM、DXS6804、DXS7132、DXS7423、
DYS391、DYS438、DYS458、EGFR、EGFR_fus、EIF4G3、EML4_fus、EP300、EPHA3、EPHA5、EPHA7、
EPHB1、ERBB2、ERBB3、ERBB4、ERCC4、ERG、ERI1、ERRFI1、ESR1、ETV1、ETV6、ETV6_fus、EWSR1_
fus、EXOSC8、EZH2、EZR_fus、F13A1、FAM149A、FAM153B、FAM46C、FANCA、FANCC、FANCD2、
FANCG、FANCI、FAS、FAT1、FBXW7、FGF16、FGF19、FGF3、FGF4、FGFR1、FGFR2、FGFR2_fus、FGFR3、
FGFR4、FH、FLCN、FLOT1、FLT1、FLT3、FLT4、FMO1、FOLH1、FOXL2、FOXP1、FRAS1、FUBP1、FUS_
fus、GABRP、GANC、GATA1、GATA2、GATA3、GLI1、GMEB1、GNA11、GNA13、GNAQ、GNAS、GPM6A、
GRIN2A、GSK3B、GSTM1、H3F3A、HAUS2、HCAR2、HEY1_fus、HGF、HLA-A、HLA-B、HLA-C、HNF1A、
HNRNPH1、HRAS、HSPA1B、HSPA4、HYOU1、IARS、ID2、ID3、IDH1、IDH2、IGF1R、IGF2、IKBKE、
IKZF1、IL7R、IL8、INHBA、INPP4B、IPO7、IRAK1、IRF4、IRF6、IRF8、IRS2、ITGAL、JAK1、JAK2、
JAK3、JUN、KCNJ2、KDM5A、KDM5C、KDM6A、KDR、KEAP1、KIAA1210、KIAA1432、KIF5B_fus、
KIR3DX1、KIT、KMT2A、KMT2C、KMT2D、KPNA4、KPNB1、KRAS、LAMA3、LEPR、LMO1、LOC100131626、
LONRF3、LRRC34、LYN、MAGOHB、MALT1、MAP2K1、MAP2K2、MAP2K4、MAP3K1、MAP3K4、MAP4K5、
MAPK1、MAPKAP1、MARK2、MCL1、MDM2、MDM4、MED12、MED19、MEF2B、MEIS1、MEN1、MET、MIR1273H、
MITF、MLH1、MMP16、MONO-27、MOV10L1、MPL、MRE11A、MRPL19、MSH2、MSH3、MSH6、MTF1、MTOR、
MTRR、MUTYH、MYADM、MYC、MYCL、MYCN、MYD88、MYO10、NAB1、NAB2_fus、NBN、NCOA6、NDUFS1、
NEO1、NF1、NF2、NFE2L2、NFKBIA、NFXL1、NKX2-1、NOTCH1、NOTCH2、NOTCH3、NPM1、NR-21、NR-
24、NR4A3_fus、NRAS、NSD1、NT5C2、NTRK1、NTRK1_fus、NTRK2、NTRK2_fus、NTRK3、NTRK3_fus、
NUP85、NUP93、P2RY8、PALB2、PAPOLG、PAQR8、PARK2、PARP1、PAX5、PBRM1、PDCD1、PDCD1LG2、
PDE6C、PDGFB_fus、PDGFRA、PDGFRB、PDPN、PIGF、PIK3C2G、PIK3CA、PIK3CB、PIK3CG、PIK3R1、
PIK3R2、PLCG2、PLEKHA1、PLEKHH2、PMS2、PNO1、POLD1、POLE、PPARG、PPHLN1_fus、PPP2R1A、
PRDM1、PREX2、PRKAR1A、PRKCI、PRPF39、PTCH1、PTEN、PTPN11、PTPRJ、PURA、RABGAP1L、RAC1、
RAD21、RAD50、RAD51、RAD51B、RAD51C、RAD51D、RAD52、RAD54L、RAF1、RARA、RB1、RBM10、
RBM27、REL、RET、RET_fus、RHOT1、RICTOR、RIPK2、RNF19A、RNF43、ROS1、ROS1_fus、RPA4、
RPTOR、RRP1B、RUNX1、RYR2、SASH1、SDHA、SDHB、SDHC、SDHD、SEL1L3、SETD2、SF3B1、SHROOM3、
SIPA1L2、SLC34A2_fus、SMAD2、SMAD3、SMAD4、SMARCA4、SMARCB1、SMO、SNX6、SOCS1、SOX2、
SOX9、SPC24、SPEN、SPOP、SRC、SS18_fus、STAG2、STAT3、STK11、STMN1、STRBP、SUCLG1、SUFU、
SUGCT、SYK、TAF15、TAGAP、TBC1D8B、TBX3、TECPR2、TERT、TET2、TGFBR2、TMEM67、TMPRSS15、
TMPRSS2、TNFAIP3、TNFRSF14、TNFSF13B、TNKS、TNRC18、TOP1、TOP2B、TP53、TPH1、TRA2A、
TRIM24、TSC1、TSC2、TSHR、TSN、TXNRD1、U2AF1、UBE2E3、UBE3C、ULK4、UPF2、UTY、VEGFA、VHL、
VSIG10, WHSC1, WHSC1L1, WT1, WWC3, XPO1, ZBBX, ZDHHC17, ZNF711, ZNF805 and ZZZ3.
7. detection kit according to claim 4, which is characterized in that the microsatellite instability site includes
rs1045642、rs1052555、rs10981694、rs11045585、rs1105525、rs1130214、rs1138272、
rs115232898、rs11572080、rs11598702、rs11615、rs12613732、rs12762549、rs13181、
rs151264360、rs1517114、rs1570360、rs1650697、rs1650723、rs1695、rs1799793、
rs1801019、rs1801131、rs1801133、rs1801265、rs1805087、rs183484、rs1934951、
rs2032582、rs2072671、rs2075252、rs2228001、rs2273618、rs2291075、rs2291767、
rs2297595、rs2494752、rs2501873、rs25487、rs2784917、rs28738963、rs316019、
rs3212986、rs3745274、rs3892097、rs3918290、rs3957357、rs4148323、rs4244285、
rs430397、rs442767、rs4646、rs4673、rs4673993、rs4728709、rs4880、rs50872、
rs55886062、rs60369023、rs67376798、rs699947、rs716274、rs7779029、rs7851395、
Rs8133052, rs8175347, rs873478, rs9679162 and rs9937.
8. it is a kind of as claimed any one in claims 1 to 3 based on the sequencing of two generations for the targeting of general cancer kind, chemotherapy and immune
The detection panel of medication or the targeting, changing for general cancer kind based on the sequencing of two generations as described in any one of claim 4 to 7
It treats and the detection kit of immune medication is being prepared for general cancer kind parting, treatment, the relevant gene mutation of prognosis, microsatellite not
Application in the device of stability site and the relevant exon region joint-detection of Tumor mutations carry calculation.
9. application according to claim 8, which is characterized in that the general cancer kind include: lung cancer, intestinal cancer, gastric cancer, liver cancer,
Breast cancer and carcinoma of endometrium.
10. application according to claim 8, which is characterized in that the joint-detection includes the detection of various mutations type,
Described includes various mutations type: point mutation, fusion, copy number variation, missing and insertion mutation；
Preferably, the application includes targeting the adjoint diagnosis of medicine, chemotherapeutic or immune substance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910074640.XA CN109609647B (en) | 2019-01-25 | 2019-01-25 | Detection Panel for pan-cancer-species targeting, chemotherapy and immune drugs based on next-generation sequencing, detection kit and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910074640.XA CN109609647B (en) | 2019-01-25 | 2019-01-25 | Detection Panel for pan-cancer-species targeting, chemotherapy and immune drugs based on next-generation sequencing, detection kit and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109609647A true CN109609647A (en) | 2019-04-12 |
| CN109609647B CN109609647B (en) | 2022-08-23 |
Family
ID=66019466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910074640.XA Active CN109609647B (en) | 2019-01-25 | 2019-01-25 | Detection Panel for pan-cancer-species targeting, chemotherapy and immune drugs based on next-generation sequencing, detection kit and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109609647B (en) |
Cited By (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110129441A (en) * | 2019-05-06 | 2019-08-16 | 臻和精准医学检验实验室无锡有限公司 | Detection panel, detection kit and its application of glioma are used for based on the sequencing of two generations |
| CN110218797A (en) * | 2019-07-26 | 2019-09-10 | 上海思路迪医学检验所有限公司 | FGFR Gene Fusion probe, detection method and kit |
| CN110229894A (en) * | 2019-05-21 | 2019-09-13 | 武汉大学 | A kind of assortment of genes and its application in the reagent that preparation prediction receives immunologic test point inhibitor for treating patient's prognosis |
| CN110257523A (en) * | 2019-07-22 | 2019-09-20 | 上海市胸科医院 | A kind of primer sets and detection method detecting chemotherapeutical medicine curative effect and side effect related SNP |
| CN110387419A (en) * | 2019-08-20 | 2019-10-29 | 裕策医疗器械江苏有限公司 | Solid tumor polygenes detects genetic chip and preparation method thereof and detection device |
| CN110468211A (en) * | 2019-10-14 | 2019-11-19 | 湖南大地同年生物科技有限公司 | Bladder cancer tumor mutant gene specific primer, kit and library constructing method |
| CN110579611A (en) * | 2019-09-18 | 2019-12-17 | 郑州大学 | Combined detection serum marker, kit and detection method for early screening and diagnosis of lung cancer |
| CN110592213A (en) * | 2019-09-02 | 2019-12-20 | 深圳市新合生物医疗科技有限公司 | Gene panel for prediction of neoantigen load and detection of genomic mutations |
| CN110656179A (en) * | 2019-10-29 | 2020-01-07 | 至本医疗科技（上海）有限公司 | Biomarker composition for immune sensitivity prediction, application and kit device storage medium |
| CN110669829A (en) * | 2019-10-19 | 2020-01-10 | 南京艾迪康医学检验所有限公司 | Primer and method for detecting mutation site c.1235C & gtT of No. 14 exon of FANCA gene |
| CN110747275A (en) * | 2019-11-21 | 2020-02-04 | 中国医学科学院肿瘤医院 | Tumor cell marker molecule and application thereof |
| CN110806479A (en) * | 2019-11-15 | 2020-02-18 | 复旦大学附属肿瘤医院 | Detection panel of breast cancer related kinase mutation and application thereof |
| CN110904235A (en) * | 2019-12-20 | 2020-03-24 | 深圳市新合生物医疗科技有限公司 | Gene panel for detecting tumor targeted drug related gene mutation, method, application and kit |
| CN110964821A (en) * | 2019-12-17 | 2020-04-07 | 复旦大学附属中山医院 | Detection panel for predicting liver cancer metastasis mode and risk and application thereof |
| CN111321140A (en) * | 2020-03-03 | 2020-06-23 | 苏州吉因加生物医学工程有限公司 | Tumor mutation load detection method and device based on single sample |
| CN111424087A (en) * | 2020-04-09 | 2020-07-17 | 合肥诺为尔基因科技服务有限公司 | Detection Panel for pan-cancer species detection or targeted drug application based on next-generation sequencing, kit and application |
| CN111640508A (en) * | 2020-05-28 | 2020-09-08 | 上海生物信息技术研究中心 | Method for constructing pan-tumor targeted drug susceptibility state evaluation model based on high-throughput sequencing data and clinical phenotype and application |
| CN111647648A (en) * | 2020-05-21 | 2020-09-11 | 北斗生命科学(广州)有限公司 | Gene panel for detecting breast cancer gene mutation and detection method and application thereof |
| CN111662981A (en) * | 2020-06-09 | 2020-09-15 | 俊兮生物科技(上海)有限公司 | Cancer gene detection kit based on second-generation sequencing probe capture method |
| CN111863126A (en) * | 2020-05-28 | 2020-10-30 | 上海生物信息技术研究中心 | Method for constructing colorectal tumor state evaluation model and application |
| CN111979329A (en) * | 2020-09-07 | 2020-11-24 | 复旦大学附属肿瘤医院 | Pan-cancer detection panel based on next-generation sequencing technology and application thereof |
| CN111996257A (en) * | 2020-09-07 | 2020-11-27 | 复旦大学附属肿瘤医院 | Gastric cancer detection panel based on next-generation sequencing technology and application thereof |
| CN112626213A (en) * | 2020-12-28 | 2021-04-09 | 复旦大学附属肿瘤医院 | Liver cancer detection panel based on next-generation sequencing technology, kit and application thereof |
| CN112961920A (en) * | 2021-03-24 | 2021-06-15 | 臻和(北京)生物科技有限公司 | Method and product for predicting curative effect of combination of immune checkpoint inhibitor and targeted therapy of hepatobiliary tumor patient |
| CN113337603A (en) * | 2021-04-23 | 2021-09-03 | 深圳市龙华区人民医院 | Application and detection kit of SUCLG1 gene or expression product thereof |
| CN113493838A (en) * | 2021-09-06 | 2021-10-12 | 北京泱深生物信息技术有限公司 | Endometrial cancer related marker molecule and application thereof in diagnosis of endometrial cancer |
| CN113493863A (en) * | 2021-06-23 | 2021-10-12 | 华中科技大学同济医学院附属同济医院 | Molecular marker for detecting COVID-19 susceptibility, kit and application |
| CN113652484A (en) * | 2021-08-03 | 2021-11-16 | 苏州京脉生物科技有限公司 | Application of sequencing panel, kit and preparation method of sequencing library |
| CN113736878A (en) * | 2021-08-24 | 2021-12-03 | 复旦大学附属肿瘤医院 | Gene panel for detecting nervous system tumor, kit and application thereof |
| CN113913518A (en) * | 2021-08-31 | 2022-01-11 | 广州市金域转化医学研究院有限公司 | Typing marker of mature B cell tumor and application thereof |
| CN114480660A (en) * | 2022-04-02 | 2022-05-13 | 普瑞基准科技（北京）有限公司 | Gene Panel for detecting pan-cancer species, probe and application |
| CN114540488A (en) * | 2020-11-26 | 2022-05-27 | 福建和瑞基因科技有限公司 | Gene combination, detection device, detection kit and application for detecting tumor mutation load through high-throughput targeted sequencing |
| CN114622015A (en) * | 2021-05-13 | 2022-06-14 | 四川大学华西医院 | NGS panel for predicting postoperative recurrence of non-small cell lung cancer based on circulating tumor DNA and application thereof |
| CN115232873A (en) * | 2022-05-11 | 2022-10-25 | 北京先声医学检验实验室有限公司 | Detection composition and kit for pan-cancer chemotherapeutics guidance and application thereof |
| CN116287266A (en) * | 2023-03-07 | 2023-06-23 | 江苏先声医学诊断有限公司 | Application of DNA replication advanced region in diagnosis of flood cancer |
| CN117305456A (en) * | 2023-10-13 | 2023-12-29 | 四川大学华西医院 | Molecular marker for predicting curative effect of tumor immunotherapy and detection method |
| CN117524304A (en) * | 2024-01-08 | 2024-02-06 | 北京求臻医学检验实验室有限公司 | Detection panel and probe set for solid tumor micro focus residue and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106755501A (en) * | 2017-01-25 | 2017-05-31 | 广州燃石医学检验所有限公司 | It is a kind of to be based on detection microsatellite locus stability and the method for genome change while the sequencing of two generations |
| CN106834107A (en) * | 2017-03-10 | 2017-06-13 | 首度生物科技（苏州）有限公司 | A kind of prediction tumour system for being based on the sequencing of two generations |
| CN107974504A (en) * | 2017-10-26 | 2018-05-01 | 上海仁东医学检验所有限公司 | The method of lung cancer and colorectal cancer genetic test based on NGS methods |
| CN108753967A (en) * | 2018-06-08 | 2018-11-06 | 复旦大学附属中山医院 | A kind of gene set and its panel detection design methods for liver cancer detection |
| CN109022553A (en) * | 2018-06-29 | 2018-12-18 | 深圳裕策生物科技有限公司 | Genetic chip for Tumor mutations cutting load testing and preparation method thereof and device |
-
2019
- 2019-01-25 CN CN201910074640.XA patent/CN109609647B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106755501A (en) * | 2017-01-25 | 2017-05-31 | 广州燃石医学检验所有限公司 | It is a kind of to be based on detection microsatellite locus stability and the method for genome change while the sequencing of two generations |
| CN106834107A (en) * | 2017-03-10 | 2017-06-13 | 首度生物科技（苏州）有限公司 | A kind of prediction tumour system for being based on the sequencing of two generations |
| CN107974504A (en) * | 2017-10-26 | 2018-05-01 | 上海仁东医学检验所有限公司 | The method of lung cancer and colorectal cancer genetic test based on NGS methods |
| CN108753967A (en) * | 2018-06-08 | 2018-11-06 | 复旦大学附属中山医院 | A kind of gene set and its panel detection design methods for liver cancer detection |
| CN109022553A (en) * | 2018-06-29 | 2018-12-18 | 深圳裕策生物科技有限公司 | Genetic chip for Tumor mutations cutting load testing and preparation method thereof and device |
Non-Patent Citations (2)
| Title |
|---|
| BÁRBARA MELÉNDEZ,: "Methods of measurement for tumor mutational burden in tumor tissue", 《TRANSLATIONAL LUNG CANCER RESEARCH》 * |
| YONGQIAN SHU: "Circulating Tumor DNA Mutation", 《SCIENTIFIC REPORTS》 * |
Cited By (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110129441B (en) * | 2019-05-06 | 2023-12-01 | 臻和精准医学检验实验室无锡有限公司 | Detection panel for brain glioma based on second-generation sequencing, detection kit and application of detection panel |
| CN110129441A (en) * | 2019-05-06 | 2019-08-16 | 臻和精准医学检验实验室无锡有限公司 | Detection panel, detection kit and its application of glioma are used for based on the sequencing of two generations |
| CN110229894A (en) * | 2019-05-21 | 2019-09-13 | 武汉大学 | A kind of assortment of genes and its application in the reagent that preparation prediction receives immunologic test point inhibitor for treating patient's prognosis |
| CN110257523A (en) * | 2019-07-22 | 2019-09-20 | 上海市胸科医院 | A kind of primer sets and detection method detecting chemotherapeutical medicine curative effect and side effect related SNP |
| CN110218797B (en) * | 2019-07-26 | 2023-03-31 | 上海思路迪医学检验所有限公司 | FGFR gene fusion probe, detection method and kit |
| CN110218797A (en) * | 2019-07-26 | 2019-09-10 | 上海思路迪医学检验所有限公司 | FGFR Gene Fusion probe, detection method and kit |
| CN110387419A (en) * | 2019-08-20 | 2019-10-29 | 裕策医疗器械江苏有限公司 | Solid tumor polygenes detects genetic chip and preparation method thereof and detection device |
| CN110592213A (en) * | 2019-09-02 | 2019-12-20 | 深圳市新合生物医疗科技有限公司 | Gene panel for prediction of neoantigen load and detection of genomic mutations |
| CN110579611A (en) * | 2019-09-18 | 2019-12-17 | 郑州大学 | Combined detection serum marker, kit and detection method for early screening and diagnosis of lung cancer |
| CN110579611B (en) * | 2019-09-18 | 2023-01-31 | 郑州大学 | Combined detection serum marker, kit and detection method for early screening and diagnosis of lung cancer |
| CN110468211B (en) * | 2019-10-14 | 2020-02-14 | 湖南大地同年生物科技有限公司 | Bladder cancer tumor mutant gene specific primer, kit and library construction method |
| CN110468211A (en) * | 2019-10-14 | 2019-11-19 | 湖南大地同年生物科技有限公司 | Bladder cancer tumor mutant gene specific primer, kit and library constructing method |
| CN110669829A (en) * | 2019-10-19 | 2020-01-10 | 南京艾迪康医学检验所有限公司 | Primer and method for detecting mutation site c.1235C & gtT of No. 14 exon of FANCA gene |
| CN110656179A (en) * | 2019-10-29 | 2020-01-07 | 至本医疗科技（上海）有限公司 | Biomarker composition for immune sensitivity prediction, application and kit device storage medium |
| CN110806479A (en) * | 2019-11-15 | 2020-02-18 | 复旦大学附属肿瘤医院 | Detection panel of breast cancer related kinase mutation and application thereof |
| CN110747275A (en) * | 2019-11-21 | 2020-02-04 | 中国医学科学院肿瘤医院 | Tumor cell marker molecule and application thereof |
| CN110964821A (en) * | 2019-12-17 | 2020-04-07 | 复旦大学附属中山医院 | Detection panel for predicting liver cancer metastasis mode and risk and application thereof |
| CN110904235A (en) * | 2019-12-20 | 2020-03-24 | 深圳市新合生物医疗科技有限公司 | Gene panel for detecting tumor targeted drug related gene mutation, method, application and kit |
| CN111321140A (en) * | 2020-03-03 | 2020-06-23 | 苏州吉因加生物医学工程有限公司 | Tumor mutation load detection method and device based on single sample |
| CN111321140B (en) * | 2020-03-03 | 2021-08-06 | 苏州吉因加生物医学工程有限公司 | Tumor mutation load detection method and device based on single sample |
| CN111424087A (en) * | 2020-04-09 | 2020-07-17 | 合肥诺为尔基因科技服务有限公司 | Detection Panel for pan-cancer species detection or targeted drug application based on next-generation sequencing, kit and application |
| CN111647648A (en) * | 2020-05-21 | 2020-09-11 | 北斗生命科学(广州)有限公司 | Gene panel for detecting breast cancer gene mutation and detection method and application thereof |
| CN111863126A (en) * | 2020-05-28 | 2020-10-30 | 上海生物信息技术研究中心 | Method for constructing colorectal tumor state evaluation model and application |
| CN111640508B (en) * | 2020-05-28 | 2023-08-01 | 上海市生物医药技术研究院 | Method and application of pan-tumor targeted drug sensitivity state assessment model constructed based on high-throughput sequencing data and clinical phenotypes |
| CN111863126B (en) * | 2020-05-28 | 2024-03-26 | 上海市生物医药技术研究院 | Method for constructing colorectal tumor state evaluation model and application |
| CN111640508A (en) * | 2020-05-28 | 2020-09-08 | 上海生物信息技术研究中心 | Method for constructing pan-tumor targeted drug susceptibility state evaluation model based on high-throughput sequencing data and clinical phenotype and application |
| CN111662981A (en) * | 2020-06-09 | 2020-09-15 | 俊兮生物科技(上海)有限公司 | Cancer gene detection kit based on second-generation sequencing probe capture method |
| CN111996257A (en) * | 2020-09-07 | 2020-11-27 | 复旦大学附属肿瘤医院 | Gastric cancer detection panel based on next-generation sequencing technology and application thereof |
| CN111979329A (en) * | 2020-09-07 | 2020-11-24 | 复旦大学附属肿瘤医院 | Pan-cancer detection panel based on next-generation sequencing technology and application thereof |
| CN114540488B (en) * | 2020-11-26 | 2024-04-30 | 福建和瑞基因科技有限公司 | Gene combination, detection device, detection kit and application for detecting tumor mutation load by high-throughput targeted sequencing |
| CN114540488A (en) * | 2020-11-26 | 2022-05-27 | 福建和瑞基因科技有限公司 | Gene combination, detection device, detection kit and application for detecting tumor mutation load through high-throughput targeted sequencing |
| CN112626213A (en) * | 2020-12-28 | 2021-04-09 | 复旦大学附属肿瘤医院 | Liver cancer detection panel based on next-generation sequencing technology, kit and application thereof |
| CN112961920A (en) * | 2021-03-24 | 2021-06-15 | 臻和(北京)生物科技有限公司 | Method and product for predicting curative effect of combination of immune checkpoint inhibitor and targeted therapy of hepatobiliary tumor patient |
| CN113337603A (en) * | 2021-04-23 | 2021-09-03 | 深圳市龙华区人民医院 | Application and detection kit of SUCLG1 gene or expression product thereof |
| CN114622015A (en) * | 2021-05-13 | 2022-06-14 | 四川大学华西医院 | NGS panel for predicting postoperative recurrence of non-small cell lung cancer based on circulating tumor DNA and application thereof |
| CN114622015B (en) * | 2021-05-13 | 2023-05-05 | 四川大学华西医院 | NGS panel for predicting postoperative recurrence of non-small cell lung cancer based on circulating tumor DNA and application thereof |
| CN113493863A (en) * | 2021-06-23 | 2021-10-12 | 华中科技大学同济医学院附属同济医院 | Molecular marker for detecting COVID-19 susceptibility, kit and application |
| CN113652484A (en) * | 2021-08-03 | 2021-11-16 | 苏州京脉生物科技有限公司 | Application of sequencing panel, kit and preparation method of sequencing library |
| CN113736878A (en) * | 2021-08-24 | 2021-12-03 | 复旦大学附属肿瘤医院 | Gene panel for detecting nervous system tumor, kit and application thereof |
| CN113913518A (en) * | 2021-08-31 | 2022-01-11 | 广州市金域转化医学研究院有限公司 | Typing marker of mature B cell tumor and application thereof |
| CN113913518B (en) * | 2021-08-31 | 2022-08-16 | 广州市金域转化医学研究院有限公司 | Typing marker of mature B cell tumor and application thereof |
| CN113493838A (en) * | 2021-09-06 | 2021-10-12 | 北京泱深生物信息技术有限公司 | Endometrial cancer related marker molecule and application thereof in diagnosis of endometrial cancer |
| CN113493838B (en) * | 2021-09-06 | 2021-11-23 | 北京泱深生物信息技术有限公司 | Endometrial cancer related marker molecule and application thereof in diagnosis of endometrial cancer |
| CN114480660A (en) * | 2022-04-02 | 2022-05-13 | 普瑞基准科技（北京）有限公司 | Gene Panel for detecting pan-cancer species, probe and application |
| CN115232873A (en) * | 2022-05-11 | 2022-10-25 | 北京先声医学检验实验室有限公司 | Detection composition and kit for pan-cancer chemotherapeutics guidance and application thereof |
| CN116287266A (en) * | 2023-03-07 | 2023-06-23 | 江苏先声医学诊断有限公司 | Application of DNA replication advanced region in diagnosis of flood cancer |
| CN117305456A (en) * | 2023-10-13 | 2023-12-29 | 四川大学华西医院 | Molecular marker for predicting curative effect of tumor immunotherapy and detection method |
| CN117524304A (en) * | 2024-01-08 | 2024-02-06 | 北京求臻医学检验实验室有限公司 | Detection panel and probe set for solid tumor micro focus residue and application thereof |
| CN117524304B (en) * | 2024-01-08 | 2024-03-29 | 北京求臻医学检验实验室有限公司 | Detection panel and probe set for solid tumor micro focus residue and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109609647B (en) | 2022-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109609647A (en) | Detection Panel, detection kit and its application for the targeting of general cancer kind, chemotherapy and immune medication based on the sequencing of two generations | |
| US11001837B2 (en) | Low-frequency mutations enrichment sequencing method for free target DNA in plasma | |
| CN109880910B (en) | Detection site combination, detection method, detection kit and system for tumor mutation load | |
| CN111321140B (en) | Tumor mutation load detection method and device based on single sample | |
| CN104293938B (en) | Build the method and its application of sequencing library | |
| JP6905934B2 (en) | Multiple gene analysis of tumor samples | |
| CN110129441B (en) | Detection panel for brain glioma based on second-generation sequencing, detection kit and application of detection panel | |
| JP2020530290A (en) | Methods and Substances for Assessing and Treating Cancer | |
| CN109196359A (en) | For assessing the method and system of Tumor mutations load | |
| CN109427412A (en) | For detecting the combined sequence and its design method of Tumor mutations load | |
| CN104294371B (en) | Build method and its application of sequencing library | |
| Liu et al. | The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility | |
| US10947599B2 (en) | Tumor mutation burden | |
| CN112626213A (en) | Liver cancer detection panel based on next-generation sequencing technology, kit and application thereof | |
| CN111996257A (en) | Gastric cancer detection panel based on next-generation sequencing technology and application thereof | |
| CN113249483B (en) | Gene combination, system and application for detecting tumor mutation load | |
| TWI683904B (en) | Method for efficiently detecting ctDNA in samples | |
| CN114480660A (en) | Gene Panel for detecting pan-cancer species, probe and application | |
| US20220399080A1 (en) | Methods and products for minimal residual disease detection | |
| CN111979329A (en) | Pan-cancer detection panel based on next-generation sequencing technology and application thereof | |
| CN111424087A (en) | Detection Panel for pan-cancer species detection or targeted drug application based on next-generation sequencing, kit and application | |
| CN114187964A (en) | Construction method of lung cancer perioperative molecular residual lesion gene detection panel and detection model | |
| CN114752672B (en) | Detection panel for prognosis evaluation of follicular lymphoma based on circulating free DNA mutation, kit and application | |
| CN114512184A (en) | Method for predicting cancer curative effect and prognosis, device and application thereof | |
| CN114438218B (en) | Gene Panel for detecting various tumors, kit and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |